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1 Introduction 
 
High-risk genital human papillomaviruses (HPV) are known to cause cervical cancer. 
Whether cutaneous HPV play an active role in the pathogenesis of non-melanoma 
skin (NMSC) cancer in the general population is currently discussed. At least in 
immunosuppressed and epidermodysplasia verruciformis (EV) patients, an 
association between cutaneous HPV and NMSC is accepted. Furthermore, an 
oncogenic potential for the cutaneous HPV type 8 could be demonstrated in 
transgenic mice, which are used as a model for HPV8-dependent NMSC 
development in this study. 
 
1.1 Papillomavirus structure 
 
Papillomaviruses (PV) are small (∅ 55nm), non-enveloped, double stranded DNA 
viruses. Their icosahedral capsid consists of 72 capsomeres. The DNA is associated 
with cellular histones building a nucleosome-like structure (Favre et al. 1977). HPV 
constitute a large, heterogeneous group, whose genome size ranges between 7200-
8000 base pairs and is typically organized in two functionally distinct regions: a non-
coding region (NCR) and a coding region (Figure 1) (Pfister and Fuchs 1994). The 
coding region comprises at least seven open reading frames (ORF) which are 
located on one DNA strand. Depending on the expression in the life cycle of the PV 
the ORF are divided in early (E) and late (L) genes. The early proteins are involved in 
replication and transcription of the PV genome and in cell transformation. The late 
proteins L1 and L2 are structural proteins building the capsid. The transcription of the 
polycistronic mRNAs starts at least from two promoters (Baker 1993). From the early 
promoter, which is located at the 3’-end of the NCR right before the E6 ORF, mRNAs 
coding for E1, E2, E5, E6 and E7 are transcribed. The late promoter controls the 
expression of L1 and L2, but also of E1, E2 and E4 (Stubenrauch et al. 1992; Pfister 
and Fuchs 1994; Stubenrauch and Laimins 1999). The length, function and 
organization of the ORFs are conserved among different PV types, despite great 
differences in sequence (Pfister and Fuchs, 1987). Due to alternative splicing a 
fusion protein named E1^E4 can be produced, which is involved in the release of 
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infectious virus particles (Doorbar et al. 1991). The NCR contains essential cis-
regulatory control elements like origin of replication (ori), promoters and a 
keratinocyte-specific enhancer, to control the viral gene expression and replication 
(Akgül et al. 2003). It is located between the L1 and E6 ORF and shows high 
similarity among closely related PV and greater differences to NCRs of other genera. 
 
 
Figure 1: Schematic drawing of the HPV8 genome. 
The HPV8 genome is divided into the early region coding for of the early genes (blue arrows), the late 
region coding for of the late genes (green arrows) and the NCR (red bar). Two promoters reside in the 
NCR (p175 and p7535). Orange bars define the functions of the encompassed genes. 
 
1.2 HPV taxonomy 
 
PV show high diversity, until now alone in humans more than 100 HPV types are fully 
sequenced (Bernard 2005). Furthermore 120 partial DNA sequences exist, 
suggested to represent putative new types (zur Hausen 2002; de Villiers et al. 2004). 
A new PV type is defined by a sequence homology below 90% within the conserved 
major capsid protein gene L1 compared to all established PV types. Differences in 
the nucleotide sequences of L1 ORF between 2-10% or less than 2% define a 
p175 p7535 
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subtype or variant, respectively (de Villiers et al. 2004). HPV are grouped in 
cutaneous and mucosal or genital HPV types, which are again divided into low-risk 
and high-risk types according to their oncogenic potential. Furthermore, HPVs can be 
classified into five genera (Alpha, Beta, Gamma, Mu und Nu). The two largest genera 
Alpha and Beta comprise 90% of the identified HPV. Genus Alpha mostly consists of 
the HPV that infect mucosal surfaces, such as the anogenital tract and the oral lining. 
Amongst these are the high risk types 16, 18 and 33 that have shown a strong 
association with the development of cervical carcinoma. The genus Beta includes 
cutaneous HPV types. Most of them were originally detected in the lesions of EV-
patients, for example HPV5 and 8. 
 
1.3 HPV life cycle 
 
HPV specifically infect keratinocytes, the predominant cell type in the epithelia 
(Eckert et al. 1997). Given that HPV infect only the epithelia, their entire life cycle, 
culminating in viral replication and virion shedding, depends upon the host cells' 
molecular machinery that is ultimately coupled to the differentiation state of 
keratinocytes. The human skin is composed of the three primary layers subcutis, 
dermis and epidermis. The epidermis is differentiated into stratum basale, stratum 
spinosum, stratum granulosum and stratum corneum (Figure 2). To establish an 
infection HPV reach the basal keratinocytes via micro traumata. Following skin 
injuries, keratinocytes express α6β4 integrin on their surface, a transmembrane 
glycoprotein, which has been proposed as a candidate receptor for HPV (Evander et 
al. 1997). Another adsorption target is heparin, which is expressed on the surface of 
the host cell (Joyce et al. 1999; Giroglou et al. 2001). Following entry into basal 
epithelial cells by endocytosis (Selinka et al. 2002), the genome is transported by a 
yet unknown mechanism into the nucleus. HPV are established and maintained as 
episomes in low copy number with the help of the early proteins, mostly E1 and E2. 
During mitosis of the infected basal cells the viral DNA which is linked to the 
chromosomes, is distributed between daughter cells (Oliveira et al. 2006), some of 
which will remain in the basal layer, while others will undergo differentiation. Because 
maturation of HPV is restricted to differentiating cells, the remaining basal cells will 
not be harmed by virus production (Stubenrauch and Laimins 1999). In the stratum 
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spinosum the expression of regulatory viral proteins increases and the vegetative 
replication of the viral DNA begins (Figure 2). Besides the viral proteins E1 and E2, 
cellular replication factors are necessary for this purpose, which are not expressed 
anymore in the suprabasal cells. Therefore the cell cycle arrest, keeping the 
keratinocytes locked in the G1-phase, is relieved by the oncoprotein E7 to permit the 
entry into the S-phase (Banerjee et al. 2006). In the uppermost layers of the stratum 
spinosum the expression of the capsid proteins L1 and L2 is induced. This 
expression is enhanced in the stratum granulosum where the maturation of the 
virions takes place. Finally, the infectious, mature viruses are shed with the squames 
of the stratum corneum (Bryan and Brown 2001). Probably the E4 protein is essential 
for this process by degrading the cytoskeleton (Doorbar et al. 1991). 
 
Figure 2: Life cycle of cutaneous HPV and profile of the skin. 
The profile shows the different layers of the skin and the maturation of HPV in dependency of skin 
differentiation (modified from Doorbar 2006). 
 
1.4 Functions of the viral proteins 
1.4.1 E2 protein 
 
The 43-48 kDa nuclear phosphoprotein E2 is involved in transcriptional regulation. It 
functionally acts as a dimer and is organized in three domains, a N-terminal 
transactivation domain, a central hinge region and a C-terminal DNA binding and 
dimerization domain. E2 facilitates the binding of the DNA helicase E1 to the viral ori 
thereby unwinding that DNA region. This process is necessary for viral replication 
(Kuo et al. 1994), as it allows access of the cellular DNA polymerase to the viral 
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genome. With the DNA binding and dimerization domain E2 dimers bind the 
palindromic motif 5’-ACCG(N)4CGGT-3’, which is present throughout the HPV 
genome, mostly within the NCR, where four copies can be found (Steger et al. 1996). 
By sterical interference, E2 dimers can act either as transactivator or repressor of E6 
and E7 transcription, depending on its own concentration (Bouvard et al. 1994; 
Enzenauer et al. 1998; Morgan et al. 1998). For example high concentrations of E2 
block the binding of the cellular activator specific protein 1 (Sp1) and TATA binding 
protein (TBP) thereby repressing promoter activity (Tan et al. 1992; Demeret et al. 
1994; Dong et al. 1994). By reducing the expression of the oncogenes E6 and E7, E2 
exerts a negative effect on cell proliferation and arrests the cells in the G2-phase 
(Frattini et al. 1997; Fournier et al. 1999). Mice, transgenic for the E2 protein of 
HPV8, spontaneously develop skin tumors, thereby showing that E2 exhibits 
transforming potential (Pfefferle et al. 2008).  
 
1.4.2 E6 protein 
 
The E6 protein of HPV is a 18 kDa phosphoprotein, which is localized in the nucleus 
and in non-nuclear membranes (Grossman et al. 1989). It contains four Cys-X-X-Cys 
motifs which form two unusually big zinc finger domains of 29-30 AA, respectively, 
which are important for protein stability and activity (Smola-Hess and Pfister, 2002). 
E6 proteins of genital high-risk HPV types carry a PDZ binding motif at the C-
terminus with the consensus sequence X-S/T-X-V/L. With this motif they are able to 
interact with PDZ domains of other proteins, for example hDlg, MAGUKs, MUPP1, 
hScrib and direct them to ubiquitin-dependent proteolysis (Gardiol et al. 1999; Lee et 
al. 2000; Nakagawa and Huibregtse 2000; Thomas et al. 2002). One major function 
of the genital HPV16-E6 protein is the inhibition of apoptosis by inactivation of p53 
(Scheffner et al. 1993). For this purpose the E6 protein forms a complex with p53 and 
the cellular ubiquitin ligase E6-associated protein (E6-AP) (Werness et al. 1990). 
This causes a deregulation of the cell cycle control at the G1/S and G2/M check 
points, an important step for the replication of HPV, because a productive infection 
cycle is only possible in cells, which are in the S-phase of the cell cycle. However, 
this cell cycle manipulation can lead to activation of oncogenes or inactivation of 
tumor suppressors and DNA damages cannot be repaired, which leads to genetic 
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instability and to malignant transformation of high-risk HPV-infected cells (Thomas 
and Laimins 1998; Somasundaram 2000; Fehrmann and Laimins 2003). Another 
important way how E6 proteins of genital HPV contribute to transformation is the 
activation of the human telomerase reverse transcriptase promoter, which controls 
the transcription of the catalytic telomerase subunit (Gewin and Galloway 2001). E6 
proteins of cutaneous HPV do not interact with p53 or E6-AP and do not degrade p53 
(Steger and Pfister 1992; Elbel et al. 1997). Nevertheless, the E6 proteins of EV-HPV 
exhibit oncogenic potential. The E6 protein of HPV5 for example can interfere with 
the repair of UVB-induced cyclobutane pyrimidine dimers (Giampieri and Storey 
2004) and the E6 protein of HPV8 can bind the cellular protein XRCC1 thereby 
impairing the repair of DNA single strand breaks (Iftner et al. 2002). Furthermore E6 
proteins of both cutaneous and anogenital HPV are able to target the proapoptotic 
protein bak for ubiquitin-dependent degradation by assembling E6-AP, thereby 
inhibiting apoptosis (Jackson and Storey 2000). 
 
1.4.3 E7 protein 
 
E7 is a 11 kDa protein with a zinc finger motif. It acts as an oncogene in genital high-
risk HPV and is able to immortalize primary foreskin keratinocytes (Halbert et al. 
1991). The major part of the transforming potential of E7 is due to the binding and 
induction of ubiquitin-dependent degradation of the tumor suppressor retinoblastoma 
protein (Rb) (Dyson et al. 1989; Berezutskaya and Bagchi 1997). The competitive 
binding of E7 to Rb and its degradation lead to the segregation of the transcription 
factor E2F. In the G1-phase, E2F is inactivated in a complex with Rb. After 
segregation, E2F can induce the expression of genes, which are important for DNA 
synthesis and cell cycle control. Additionally E7 can bind the inhibitors of cyclin-
dependent kinases p21CIP1 and p27KIP1 and inhibit their functions (Münger et al. 
2001). Both events direct the cell into the S-phase and enable the viral replication. 
Most E7 proteins of low-risk HPV and EV-HPV, including HPV8, have a much lower 
binding affinity for Rb and do not induce its degradation (Iftner et al. 1988; Kiyono et 
al. 1989; Schmitt et al. 1994). However, in organotypic skin cultures, HPV8-E7 could 
induce an invasion of keratinocytes into the dermis, implicating a direct involvement 
of E7 in the oncogenesis of cutaneous HPV-types (Akgül et al. 2006). 
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1.5 Human Papillomaviruses are involved in cervical cancer 
 
HPV is the most common sexually transmitted virus (Garland 2002). Although HPV 
can persist for years in infected tissue, in most cases an infection with HPV is 
clinically unapparent. Nevertheless, low-risk HPV types 6 and 11 can induce benign 
tumors such as warts and condylomas (zur Hausen 2000). High-risk types are 
widespread within all human populations, particularly HPV16, and an infection with 
these types result in squamous intraepithelial lesions. In most cases these lesions 
exhibit a limited growth and regress spontaneously, probably due to a cell-mediated 
immune response (Shah and Howley 1996). However, in a small percentage the 
infection persists and promotes malignant progression of epithelial tumors of the 
anogenital tract. In the course of persisting infections with high-risk HPV types 16 or 
18 the normal cell differentiation of the cervix uteri is gradually lost, resulting in 
cervical intraepithelial neoplasia. In 10-30% of these cases an invasive cervical 
carcinoma develops, worldwide the second most common cancer in women (Einstein 
and Goldberg 2002). In most carcinomas the HPV DNA is integrated into the host 
genome, which normally leads to the loss of the E2-ORF and the E2-dependent 
repression of E6 and E7 expression, thereby promoting carcinogenesis (Turek 1994; 
Wells et al. 2000; Arias-Pulido et al. 2006; Gammoh et al. 2006). In 1995 the World 
Health Organization (WHO) declared HPV as the causing factor for cervical cancer, 
because DNA of mucosal high-risk HPV types could be detected in almost 100% of 
all cervical cancers (Walboomers et al. 1999). Mainly DNA of the high-risk HPV types 
16 (44-68%), 18 (10-14%), 31 and 45 (2-8%) was detected in carcinomas (Munoz 
2000; Clifford et al. 2003). Since 2006 vaccines are available on the basis of virus 
like particles (VLP), which consist of the major capsid protein L1. Two vaccines are 
licensed in the EU, a quadrivalent vaccine including L1 VLPs from HPV6, 11, 16 and 
18 (Gardasil) and a bivalent vaccine containing L1 VLPs from HPV16 and 18 
(Cervarix), which protect from an infection with the respective HPV types.  
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1.6 Role of HPV in non-melanoma skin cancer 
 
NMSC, which includes basal cell carcinoma, squamous cell carcinoma (SCC) and 
Bowen´s disease, is the most common cancer in fair-skinned populations. The 
incidence of NMSC has epidemically increased and now represents approximately 
30% of all cancers (DePinho 2000; Alam and Ratner 2001; Pfister 2003). As 
ultraviolet (UV) radiation is the main risk factor, NMSC emerges primarily on sun-
exposed skin areas (Leiter and Garbe 2008). However, other factors than solar 
exposure, such as genetic background, immunological status and the presence of 
selected viral infections, may also be involved in determining the induction of NMSC 
(Stern 1999; Corona et al. 2001). Infections with beta-HPV are acquired early in 
infancy and most people probably carry persistent infections with multiple types 
(Antonsson et al. 2003; Weissenborn et al. 2009). A linkage between HPV and the 
development of human skin cancer is accepted for the rare, autosomal recessive, 
genetic disorder EV and the so called EV-HPV, today phylogenetically classified as 
beta-HPV (Majewski et al. 1997; Pfister and Ter Schegget 1997; de Villiers et al. 
2004). The clinical picture of EV, first described in 1922 by Lewandowsky and Lutz, is 
distinguished by a life-long occurrence of multiple flat warts and macular lesions with 
a high risk of developing SCC later in life (Jablonska and Majewski 1994; Orth 2006). 
EV-patients are somehow not able to control the HPV infection in the keratinocytes 
(Majewski et al. 1997). The tumors grow locally invasive, but are not metastatic. In 
contrast to cervical carcinoma the HPV genome is hardly ever integrated into the 
cellular genome in cutaneous SCC (Orth 2006). A genetic predisposition for EV could 
be assigned to DNA-loci on the long arm of chromosome 17 and chromosome 2 
(Ramoz et al. 2000). A mutation in one of the two genes EVER1 and EVER2 located 
on chromosome 17 is responsible for this condition (Ramoz et al. 2002). Although the 
precise function of these genes is not yet fully understood, they play an important 
role in regulating the distribution of zinc in the cell nucleus. It could be shown that 
zinc plays an essential role as cofactor for viral proteins, which is retained by the 
EVER1/EVER2 complex thereby inhibiting viral growth (Lazarczyk and Favre 2008; 
Lazarczyk et al. 2008). While about 20 different HPV types have been found in 
benign tumors of EV-patients, HPV5 or 8 were found in 90% of SCC (Pfister 2003), 
which are therefore considered high-risk types. Furthermore, these beta-HPV-types 
were found in high DNA copy numbers in SCC of EV-patients (Pfister 2003), and are 
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actively transcribed (Orth 2005). Although these HPV types were also found in the 
general population, the DNA loads are very low in the skin and in hair bulbs, which 
represent their probable reservoir (Pfister 2003; Weissenborn et al. 2009). 
Remarkably, the prevalence of HPV DNA was in SCC lower than in premalignant 
actinic keratosis (AK) suggesting an association between EV-HPV and the early 
steps of skin carcinogenesis (Pfister 2003). A high EV-HPV prevalence was also 
detected in NMSC of immunosuppressed organ transplant recipients. An etiological 
role for HPV in the development of NMSC in the genral population is a matter of 
debate, because of the high prevalence of low-level infections in the general 
population, the absence of high-risk HPV types and the low HPV DNA copy numbers 
in SCC indicating that not every tumor cell contains an HPV genome (reviewed in 
Pfister, 2003). However, seroepidemiological data and the extremely high prevalence 
of EV-HPV DNA in AK substantiated the involvement of HPV in the early 
development of NMSC of the general population. Furthermore, case-control studies 
showed that seropositivity, especially against HPV8, constitutes a significant risk for 
a NMSC diagnose (Feltkamp et al. 2003; Masini et al. 2003), demonstrating that 
HPV8 could also be a high-risk type in the general population. Moreover NMSC of 
immunesuppressed patients revealed a high prevalence of EV-HPV pointing to an 
important role of the immune system in the prevention of HPV-mediated skin cancer 
(Berkhout et al. 2000; Harwood et al. 2000; Pfister 2003). 
 
1.7 HPV transgenic mice 
 
HPV8 transgenic mouse lineages were established at our institute expressing all 
early genes of HPV8 (E1/E2/E4/E6/E7, HPV8-CER) (Schaper et al. 2005) or only E2 
(Pfefferle et al. 2008) or E6 (Marcuzzi et al. 2009). The genetic background of these 
mice is FVB/N. All transgenes are expressed under the control of the human keratin-
14 (hK14)-promoter, which directs the expression of the transgenes to the stratum 
basale of the skin, the hair follicle and to a lesser extent to the stratum spinosum. 
Almost all HPV8-CER and -E6 mice spontaneously develop papillomas, dysplasias 
and in 6% SCC. Tumors developed mostly dorsal caudal and earlier in male mice. 
Therefore, it is speculated that most of the tumors elicited from position fight wounds. 
UVA/B-irradiation or wounding by taking punch biopsies led to a synchronized 
 Introduction  10 
 
induction of papilloma development within about three weeks in these mice, while the 
skin of FVB/N wild type (wt) mice healed completely within this time (Marcuzzi 2006). 
In summary, HPV8-E6 mice perfectly mirror the HPV8-CER phenotype, including rate 
and prevalence of papillomatosis. The HPV8-E2 mouse strain used in this study 
showed spontaneous papilloma development only in 8% and UV-induced 
papillomatosis in 87% of the animals. SCC were detected in 2% in these mice, which 
showed an abnormally high amount of spindle cells (Pfefferle et al. 2008). This 
generally rare histology is characteristic for very aggressive carcinomas of 
immunosuppressed organ transplant recipients (Harwood et al. 2006). Transgenic 
CBA/C57B1 mice expressing the early region of HPV1, which causes benign warts, 
under the control of the K6-promoter showed only transient hyperproliferation 
(Tinsley et al. 1992). FVB/N mice expressing the oncoproteins E6 and E7 of HPV38 
under the control of the bovine homologue of the hK10-promoter did not develop 
spontaneous papillomas during their life of 2 to 2.5 years. Seven to eight weeks after 
treatment with DMBA and TPA, the classical two step carcinogenesis protocol, these 
animals developed several papillomas and three of eight mice developed SCC (Dong 
et al. 2005). Moreover hairless SKH-hr1 mice, expressing the oncoproteins E6 and 
E7 of HPV20 under the control of the K10-promoter, did not develop spontaneous 
tumors during the observation period of two years (Michel et al. 2006). The animals 
were then irradiated three times a week with UVB (90 to 200 mJ/cm2) beginning at an 
age of six weeks and ending at an age of 15 weeks. A slightly higher tendency for 
papillomatosis was observed in the transgenic animals compared to the control 
animals. In non-transgenic mice more papilloma regressed and the regression 
started at an earlier point in time. Altogether two SCCs were detected in HPV20-
transgenic mice.  
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1.8 RNA interference 
1.8.1 History of RNA interference 
 
RNA interference (RNAi) was first observed by plant biologists in the late 1980, 
however, its molecular mechanisms remained unclear until Fire et al. (1998) showed 
in the nematode Caenorhabditis elegans that RNAi is an evolutionarily conserved 
gene-silencing mechanism. Two types of small RNA molecules, microRNA (miRNA) 
and small interfering RNA (siRNA), are central to RNAi. This sequence-specific 
posttranscriptional gene-silencing by double-stranded RNA is conserved among 
different organisms including plants, animals and viruses (Lagos-Quintana et al. 
2001; Lau et al. 2001; Lee and Ambros 2001; Berezikov et al. 2006; Ruby et al. 
2006). Besides regulating the gene expression, this process also plays an important 
role in the defense against viruses and the mobilization of transposons (Tijsterman et 
al. 2002). 
 
1.8.2 MicroRNA-biogenesis and silencing mechanism 
 
MiRNAs are small (~ 22 nt), noncoding RNA molecules regulating the gene 
expression (Ambros 2003). Most miRNAs arise from long primary transcripts (pri-
miRNA) generated by Pol II polymerase (Figure 3) (Cai et al. 2004; Lee et al. 2004; 
Borchert et al. 2006). Pri-miRNAs form a stable stem loop, which is processed by the 
RNase III enzyme Drosha into ~70 nt long hairpin precursor miRNAs (pre-miRNA) 
(Lee et al. 2003; Han et al. 2004). Exportin 5 translocates the pre-miRNA into the 
cytoplasm, where the pre-miRNA is cleaved by the RNase III enzyme Dicer into the 
mature ~22 nt miRNA:miRNA* duplex (Bohnsack et al. 2004; Lund et al. 2004; 
Forstemann et al. 2005; Saito et al. 2005). Afterwards one of the two miRNA strands 
is incorporated into the RNA-induced silencing complex (RISC), among others 
composed of Argonaute proteins and Dicer (Gregory et al. 2005; Maniataki and 
Mourelatos 2005). The incorporated miRNA guides RISC to its target RNA by base 
pairing interactions. Depending on the degree of sequence complementarity between 
miRNA and target mRNA, the target mRNA is cleaved or translationally silenced. 
Imperfect binding leads to inhibition of translation and complete binding to cleavage 
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of the target mRNA (Ambros 2004; Bartel 2004; Diederichs and Haber 2007). Most 
miRNA targets are translationally repressed, only one endogenous animal miRNA 
target (HOXB8) has been reported to be cleaved (Yekta et al. 2004). Translationally 
repressed mRNAs are not actively degraded but can be destabilized due to 
deadenylation and subsequent decapping (Behm-Ansmant et al. 2006). The 
mechanism of translational repression by miRNAs is unclear. There is evidence that 
miRNAs block translation initiation but also that miRNAs block translation elongation 
(Maroney et al. 2006; Petersen et al. 2006). The complex of Argonaute proteins, 
miRNA and target mRNA accumulates in processing bodies (P-bodies), known 
cytoplasmic foci for mRNA degradation (Liu et al. 2005; Pillai et al. 2005). Several 
proteins in P-bodies can interact with Argonaute proteins, thereby inhibiting the 
translation (Liu et al. 2005; Behm-Ansmant et al. 2006). Although gene silencing 
typically takes place in the cytoplasm, it has also been reported to occur within the 
nucleus of human cells. In this case miRNAs induce transcriptional gene silencing 
through de novo DNA methylation of the promoter region or histone modification 
(Bayne and Allshire 2005; Tan et al. 2009). Furthermore, it has been reported that 
miRNAs can act as cis-regulators to modulate gene expression (Kim et al. 2008). 
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Figure 3: Mechanism of RNAi. 
RNAi pathways are guided by small RNAs that include siRNAs and miRNAs. The diagram describes 
the siRNA pathway (left side) and the miRNA pathway (right side) (modified from de Fourgerolles et al. 
2007). The miRNA pathway is described in detail below. The pri-miRNA generated by Pol II or Pol III 
polymerase can contain several miRNA sequences and are up to several kilobases long. Like mRNAs, 
Pol II-transcribed pri-miRNAs contain 5’ cap structure, are polyadenylated and may be spliced (Bracht 
et al. 2004; Cai et al. 2004). MiRNAs are located either within the introns or exons of protein-coding 
genes (70%) or in intergenic areas (30%) (Rodriguez et al. 2004; Kim and Kim 2007). The requirement 
for the recognition and subsequent processing of the pri-miRNA is the ability to generate a stable stem 
loop of at least 30 bp. In the nucleus this pri-miRNA stem loop is processed by a protein complex 
called the Microprocessor of which the core proteins are the RNase III enzyme Drosha and the 
double-stranded RNA-binding domain (dsRBD) protein DGCR8/Pasha into ~ 70 nt long hairpin pre-
miRNA (Lee et al. 2003; Han et al. 2004). The generated 2 nt 3’ overhang is recognized by Exportin 5 
which translocates the pre-miRNA into the cytoplasm by a Ran-GTP-dependant mechanism 
(Bohnsack et al. 2004; Lund et al. 2004). Next, the pre-miRNA is cleaved by the RNase III enzyme 
Dicer together with the dsRBD proteins TRBP/Loquacious into the mature ~22 nt miRNA:miRNA* 
duplex (Forstemann et al. 2005; Saito et al. 2005). Afterwards TRBP recruits the Argonaute protein 
Ago2 and together with Dicer they build a trimeric complex that initiates the assembly of RISC 
(Gregory et al. 2005; Maniataki and Mourelatos 2005). The miRNA strand with the thermodynamically 
lower stability of base pairing at its 5’-end is incorporated into RISC, while the miRNA* is usually 
degraded (Schwarz et al. 2003). The incorporated miRNA guides RISC to its target RNA by base 
pairing interactions, in this process the complementarity between the nucleotides 2 to 8 from the 5’-
end of the guide strand (seed region) and the target mRNA is critical (Parker et al. 2006). Depending 
on the sequence complementarity between miRNA and target mRNA the target mRNA is either 
translationally repressed or degraded. 
 
 Introduction  14 
 
1.8.3 MiRNA functions 
 
MiRNAs exhibit highly conserved sequences among different organisms indicating 
that they are under strong evolutionary pressure and have functions in essential 
processes (Pasquinelli et al. 2000; Ambros 2004). In fact, they play an important role 
in embryogenesis and cell differentiation but also by regulating the cell cycle and 
apoptosis (Harfe 2005; Carleton et al. 2007). The expression is strongly cell- and 
tissue-dependent (Zhao and Srivastava 2007). For the human genome 721 miRNA 
sequences are listed in the Sanger mirBase: release 14.0, which are predicted to 
regulate about 30 % of all human genes (Lewis et al. 2005). Half of these human 
miRNAs are located inside or near fragile sites of the chromosomes and in regions, 
which are associated with cancer (Calin et al. 2004), suggesting that miRNA 
dysregulations have substantial impact on carcinogenic processes. Several studies 
already reported that miRNAs are involved in the primary steps of carcinogenesis 
and its progression (Calin et al. 2002; Croce and Calin 2005; Iorio et al. 2005; Volinia 
et al. 2006). Some of these miRNAs are known to target oncogenes or tumor 
suppressors (Table 1). Interestingly, in preliminary experiments the HPV8-CER 
mouse also showed deregulated miRNA expressions (Reinartz 2007). 
 
MicroRNA Confirmed targets Reference 
miRNA-let-7a  RAS, c-myc (Johnson et al. 2005; 
Sampson et al. 2007) 
miRNA-15a 
miRNA-16-1 
Bcl-2 (Cimmino et al. 2005) 
miRNA-17-92 cluster E2F1, Bim, PTEN (reviewed in Garzon et 
al. 2009) 
miRNA-21 PTEN, PDCD4, TPM1 (Meng et al. 2007; Zhu et 
al. 2007; Frankel et al. 
2008) 
miRNA-34a,b,c CDK4, CDK6, cyclinE2, E2F3 (reviewed in Garzon et 
al. 2009) 
miRNA-106a Rb (Volinia et al. 2006) 
miRNA-155 KGF (Pottier et al. 2009) 
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miRNA-203 ∆Np63,  (Yi et al. 2008) 
miRNA-206 MET (Yan et al. 2009) 
miRNA-218 LAMB3 (Martinez et al. 2008) 
miRNA-372,373 LATS2 (Voorhoeve et al. 2007) 
Table 1: MiRNAs and their respective known targets. 
 
1.8.4 Small interfering RNA biogenesis and silencing mechanism 
 
Endogenous siRNAs derive from double stranded RNAs (dsRNAs) produced by 
transposable elements, complementary annealed transcripts or replicating viruses. 
Similar to the miRNA biogenesis the dsRNAs are processed by Dicer into siRNA 
duplexes of 19-25 bp (Figure 3) (Bernstein et al. 2001). These duplexes are 
incorporated into RISC, whereupon an ATP-dependent helicase unwinds the duplex, 
enabling one of the two strands to independently identify its target mRNA (Kisielow et 
al. 2002). In contrast to miRNAs, siRNAs bind their target mRNA with perfect 
complementarity inducing RISC to cleave the mRNA strand between the nucleotides 
that are complementary to nucleotides 10 and 11 of the guide strand relative to the 
5′-end (Caudy et al. 2003). The cleavage products are released and degraded. This 
mechanism of gene regulation has provided a powerful new tool for biological 
research and drug discovery by using synthetic siRNA duplexes. 
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1.9  Aim of the study 
 
The transgenic mouse line HPV8-CER, expressing all early genes of HPV8, shows 
spontaneous papilloma development, predominantly on scratched skin areas. 
Furthermore a single UVA/B-dose leads to papilloma development within three 
weeks in these mice, while the skin of FVB/N wt mice heals completely within this 
time. 
In order to clarify the role of skin wounding and its influence on HPV expression in 
the early stages of tumor development in this mouse model, the kinetics and levels of 
transgene expression were analyzed in response to exogenous skin irritations, 
including UVA/B-irradiation and mechanical wounding. To narrow down the time 
period during which the HPV8-E6 oncogene expression is necessary for 
transformation in HPV8-CER mice, HPV8-E6 specific siRNA was topically applied on 
mouse skin. Based on the initial observation, that HPV8-CER mice showed 
deregulated expressions of cellular miRNAs (Reinartz 2007), the expression kinetics 
of selected miRNAs and their respective targets were determined after UVA/B-
irradiation, to check for a correlation with HPV oncogene expression.  
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2 Material 
 
2.1 Bacterial strain 
 
 Epicurian coli ® XL1-Blue 
genotype: recA1, end A1, gyr96, thi-1, hsdR17, supE44, relA1, lac[F’proAB 
lacqZ∆AM15 Tn10(Tetr)] (Stratagene, La Jolla, USA)  
 
2.2 Eukaryotic cells 
 
 HaCaT 
A spontaneously immortalized, aneuploid, human, keratinocyte cell line 
derived from human skin, which kept the characteristics of differentiation. It 
shows a transforming phenotype, but is not tumorigenic. Contains mutated 
p53 (Boukamp et al. 1988). 
 HaCaT-pLXSN8-E6 
HaCaT cell line retrovirally transduced with pLXSN8-E6, expresses HPV8-E6 
(present work) 
 PM1 
A premalignant keratinocyte cell line, contains wt p53 
 PM1-pLXSN 
PM1 cell line, retrovirally transduced with the empty vector pLXSN 
(present work) 
 PM1-pLXSN8-CER 
PM1 cell line, retrovirally transduced with pLXSN8-CER, expresses the early 
genes of HPV8 (present work) 
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2.3 Nucleic acids 
2.3.1 Synthetic oligonucleotides 
 
The HPLC purified oligonucleotides were ordered from TIB MOLBIOL (Berlin), except 
for the oligo-dT23-primer, which was purchased from Sigma-Aldrich (Steinheim). 
Numbers define the position of the oligonucleotides in the respective gene. 
 
2.3.1.1 Oligonucleotides for quantitative real-time PCR (mRNA) 
Name Sequence 5’→3’ Position 
β-actin (human) 
forward 
TCCCTGGAGAAGAGCTACGA 787 - 806 
(NM_001101)1 
β-actin (human) 
forward 
AGCACTGTGTTGGCGTACAG 961 - 980 
(NM_001101)1 
β-actin (murine) 
forward 
CCAGAGCAAGAGAGGTATCCTGAC 
Tann 55°C 
253 - 276 
(NM_007393)1 
β-actin (murine) 
reverse 
CATTGTAGAAGGTGTGGTGCCAG 
Tann 55°C 
334 - 356 
(NM_007393)1 
B2m (murine) 
forward 
ATTCACCCCCACTGAGACTG 
Tann 50°C 
318 - 337 
(NM_009735)1  
RTPrimerDB2 
ID: 2866 
B2m (murine) 
reverse 
TGCTATTTCTTTCTGCGTGC 
Tann 50°C 
491 - 510 
(NM_009735)1  
RTPrimerDB2 
ID: 2866 
HPRT1 (human) 
forward 
TGACACTGGCAAAACAATGCA 
Tann 55°C 
577 - 598 
(NM_000194)1 
RTPrimerDB2 ID: 5 
HPRT1 (human) 
reverse  
GGTCCTTTTCACCAGCAAGCT 
Tann 55°C 
650 - 671 
(NM_000194)1 
RTPrimerDB2 ID: 5 
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HPRT1 (murine) 
forward 
CCTAAGATGAGCGCAAGTTGAA 
Tann 55°C 
798 - 820 
(NM_013556) 
RTPrimerDB2 
ID: 45 
HPRT1 (murine) 
reverse  
CCACAGGACTAGAACACCTGCTAA 
Tann 55°C 
860 - 884 
(NM_013556)1 
RTPrimerDB2 
ID: 45 
HPV8E2 
forward  
AACAGCCACAACAAACCG 
Tann 50°C 
3410 - 3427  
(M12737)1 
HPV8E2 
reverse  
AGGACCTGGACCTGGATACG 
Tann 50°C 
3567 - 3586 
(M12737)1 
HPV8E6 
forward 
GCAACGTTTGAATTTA 
Tann 50°C 
433 - 448 
(M12737)1 
HPV8E6 
reverse  
CATGATACAAATGCTTAC 
Tann 50°C 
638 - 655 
(M12737)1 
HPV8E7 
forward 
CCTGAAGTGTTACCAGTTGACCTGC 
Tann 50°C 
710 - 734  
(M12737)1 
HPV8E7 
reverse  
CAGTTGCGTTGACAAAAAGACG 
Tann 50°C 
848 - 869  
(M12737)1 
K14 (murine) 
forward 
TCCAGAGATGTGACCTCC 
Tann 50°C 
1403 - 1420 
(NM_016958) 
K14 (murine) 
reverse   
CCACCTTGCCATCGT 
Tann 50°C 
1458 - 1472 
(NM_016958)1 
1
 Accession number, 2 primer ID from the primer databas RTPrimerDB 
 
2.3.1.2 Oligonucleotides for quantitative real-time PCR (miRNA) 
Name Sequence 5’→3’ Position 
mmu-let-7a TGAGGTAGTAGGTTGTATAGT MIMAT00005211 
mmu-miR-7  TGGAAGACTAGTGATTTTGTT MIMAT00006771 
mmu-miR-15a TAGCAGCACATAATGGTTTG MIMAT00005261 
mmu-miR-16 TAGCAGCACGTAAATATTGG MIMAT00005271 
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mmu-miR-17-5p CAAAGTGCTTACAGTGCAGGTAG MIMAT00006491 
mmu-miR-19a/b TGTGCAAATCYATGCAAAACT MIMAT0000651/1 
MIMAT00005131 
mmu-miR-20b CAAAGTGCTCATAGTGCAGGTA MIMAT00031871 
mmu-miR-21 TAGCTTATCAGACTGATGTTGA MIMAT00005301 
mmu-miR-34a TGGCAGTGTCTTAGCTGGTT MIMAT00005421 
mmu-miR-92 TATTGCACTTGTCCCG MIMAT00005391 
mmu-miR-106a CAAAGTGCTAACAGTGCAGGTA MIMAT00003851 
mmu-miR-127 TCGGATCCGTCTGAGCTT MIMAT00001391 
mmu-miR-133a* GCTGGTAAAATGGAACCAA MIMAT00034731 
mmu-miR-133a/b TTGGTCCCCTTCAACCAGC MIMAT0000145/1 
MIMAT00007691 
mmu-miR-145 AATGGCGCCACTAGGGTTGTGCA MIMAT00001571 
mmu-miR-155 TTAATGCTAATTGTGATAGG MIMAT00001651 
mmu-miR-200a/141 TAACACTGTCTGGTAACGATG MIMAT0000519/1 
MIMAT00001531 
mmu-miR-206 TGGAATGTAAGGAAGTGTGTGG MIMAT00002391 
mmu-miR-207 GCTTCTCCTGGCTCTCCTCCCTC MIMAT00002401 
mmu-miR-218 TTGTGCTTGATCTAACCATGT MIMAT00006631 
mmu-miR-224 TAAGTCACTAGTGGTTCCGTTTA MIMAT00006711 
mmu-miR-290 CTCAAACTATGGGGGCACTTTTT MIMAT00003661 
mmu-miR-346 TGTCTGCCCGAGTGCCTGCCTCT MIMAT00005971 
mmu-miR-347-5p ATATAATACAACCTGCTAAGT MIMAT00037271 
mmu-miR-467a ATATACATACACACACCTACAC MIMAT00034091 
mmu-miR-467b ATATACATACACACACCAACAC MIMAT00054481 
mmu-miR-468 TATGACTGATGTGCGTGTGTCTG MIMAT00021091 
mmu-miR-652 AATGGCGCCACTAGGGTTGTGCA MIMAT00037111 
mmu-miR-680 GGGCATCTGCTGACATGGGGG MIMAT00034571 
mmu-miR-698 CGTCCCCGCTCGGCGGGGTCC MIMAT00034881 
mmu-miR-721 CAGTGCAATTAAAAGGGGGAA MIMAT00035151 
miRNA reverse GCGAGCACAGAATTAATACGAC 
adapted from Shi et al. (2005) 
 
1
 Accession number, Tann was for all oligonucleotides 60°C 
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2.3.1.3 Oligonucleotides for sequencing 
Name Sequence 5’→3’ Position 
pJETseq GGAGCAGGTTCCATTCATTG 387 – 406 in pJET1/blunt 
 
2.3.1.4 Oligonucleotides for reverse transcription 
Name Sequence 5’→3’ 
Oligo-dT23-Primer (T)23V 
Random Nonamers (N)9 
miRNA adaptor GCGAGCACAGAATTAATACGACTCACTATAGG(T)12VN 
adapted from Shi and Chiang (2005) 
V = A, C, G; N = A, C, G, T 
  
2.3.1.5 Oligonucleotides for in situ hybridization probes 
Name Sequence 5’→3’ 
as-mmu-miR-21 +TC+AA+CA+TC+AG+TC+TG+AT+AA+GC+TA 
as-mmu-miR-106a +CT+AC+CT+GC+AC+TG+TT+AG+CA+CT+TT+G 
as-mmu-miR-155 +ACC+CCT+ATC+ACA+ATT+AGC+ATT+AA 
as-mmu-miR-206 +CCA+CAC+ACT+TCC+TTA+CAT+TCC+A 
+ = locked nucleic acid (LNA) 
 
2.3.2 siRNA duplex 
 
The HPLC purified siRNA duplex were either ordered from Qiagen (Hilden) or 
Biospring (Frankfurt am Main). Numbers define the position of the siRNA in the HPV8 
genome (M12737) 
 
 
Name Sequence 5’→3’ Target 
siRNA-HPV8E6-1 
sense 
CCGCAACGUUUGAAUUUAAdTdT HPV8-E6 431-449 
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siRNA-HPV8E6-1 
antisense  
UUAAAUUCAAACGUUGCGGdTdT 
siRNA-HPV8E6-2 
sense 
GGAGUUUGCAGGCUUUGUAdTdT  HPV8-E6 622-640 
siRNA-HPV8E6-2 
antisense  
UACAAAGCCUGCAAACUCCdTdT 
siRNA-HPV8E6-3 
sense 
AGGCAGAGAUAUUGAAUUAdTdT HPV8-E6 474-492 
siRNA-HPV8E6-3 
antisense  
UAAUUCAAUAUCUCUGCCUdAdG 
siRNA-HPV8E6-4 
sense 
GGAUAUCAUAGAGAAAUUAdTdT HPV8-E6 552-570 
siRNA-HPV8E6-4 
antisense  
UAAUUUCUCUAUGAUAUCCdAdA 
siRNA-control-
fluorescein sense 
UUCUCCGAACGUGUCACGUdTdT non targeting, 
linked with a 
fluorescein molecule siRNA-control-
fluorescein antisense 
UUCUCCGAACGUGUCACGUdTdT 
 
2.3.3 Cloning vectors 
 
 pJET1/Blunt (3,1 kb) blunt-end cloning vector from GeneJET™ PCR Cloning 
Kit (Fermentas, St. Leon-Rot). PCR products were ligated into this vector to 
prepare serial dilutions to generate a standard curve in qPCR experiments. 
 
2.3.4 Retroviral expression vectors 
 
 pLXSN (5.9Kb) a retroviral expression vector which can be transfected into a 
packaging cell line. These cells secrete recombinant retroviruses into the 
supernatant, which can be used to transduce cells. The gene of interest is 
expressed under the control of the 5’-LTR promoter. Contains neomycin 
resistance gene (Clontech, Heidelberg). 
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2.3.5 Recombinant plasmids 
 
 pJET1-hHPRT1 (3,2 kb) human HPRT1 PCR product cloned into pJET1/Blunt 
to prepare serial dilutions to generate a standard curve in qPCR experiments 
(present work). 
 pJET1-mHPRT1 (3,2 kb) murine HPRT1 PCR product cloned into 
pJET1/Blunt to prepare serial dilutions to generate a standard curve in qPCR 
experiments (present work). 
 pJET1-hβ-actin (3,3 kb) human β-actin PCR product cloned into pJET1/Blunt 
to prepare serial dilutions to generate a standard curve in qPCR experiments 
(present work). 
 pJET1-mβ-actin (3,2 kb) murine β-actin PCR product cloned into pJET1/Blunt 
to prepare serial dilutions to generate a standard curve in qPCR experiments 
(present work). 
 pJET1-mK14 (3,2 kb) murine K14 PCR product cloned into pJET1/Blunt to 
prepare serial dilutions to generate a standard curve in qPCR experiments 
(present work). 
 pLXSN-8E6 (6,4 kb) the early gene E6 of HPV8 was amplified by PCR and 
cloned into EcoRI/BamHI-digested retroviral vector pLXSN. Recombinant 
retroviruses can be produced when transfected into pT67 cells (Akgül et al. 
2007).  
 pLXSN-CER (11 kb) the complete early coding region of HPV8 (nt. 1 - 5111) 
was cloned by inserting the HpaI/BamHI fragment of HPV8 into the retroviral 
vector pLXSN. Recombinant retroviruses can be produced when transfected 
into pT67 cells (Akgül et al. 2007). 
 
2.3.6 DNA markers and loading dyes 
 
 6X DNA Loading Dye    (Fermentas, St. Leon-Rot) 
 6X Orange DNA Loading Dye   (Fermentas, St. Leon-Rot) 
 GeneRuler™ 100bp DNA ladder   (Fermentas, St. Leon-Rot) 
 GeneRuler™ 1kb DNA ladder   (Fermentas, St. Leon-Rot) 
 GeneRuler™ DNA Ladder, Low Range  (Fermentas, St. Leon-Rot) 
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2.3.7 Miscellaneous nucleic acids 
 
 Adenosine 5'-triphosphate    (Fermentas, St. Leon-Rot) 
 Deoxynucleotide triphosphates   (Fermentas, St. Leon-Rot) 
 Single stranded salmon sperm DNA  (Sigma-Aldrich, Steinheim) 
 
2.4 DNA preparation 
 
 DIG Oligonucleotide 3´-End Labeling Kit”  (Roche Diagnostics, Mannheim) 
 DirectPCR Lysis Reagent (Tail)   (PEQLAB, Erlangen) 
 GeneJET™ Plasmid Miniprep Kit  (Fermentas, St. Leon-Rot) 
 GeneJET™ PCR Cloning Kit    (Fermentas, St. Leon-Rot) 
 PureLink™ HiPure Plasmid Filter Maxiprep Kit     
       (Invitrogen, Karlsruhe) 
 QIAprep 8 Miniprep Kit    (Qiagen, Hilden) 
 QIAquick Gel Extraction Kit   (Qiagen, Hilden) 
 QIAquick PCR Purification Kit   (Qiagen, Hilden) 
 QIAprep Spin Miniprep Kit    (Qiagen, Hilden) 
 
2.5 Transfection reagents 
 
 HiPerFect Transfection Reagent   (Qiagen, Hilden) 
 In vivo-jetPEI     (PEQLAB, Erlangen) 
 Lipofectamine 2000    (Invitrogen, Karlsruhe) 
 MIKA-Nuclehicle-Kit    (MIKA Pharma GmbH,  
       Bad Oeyenhausen) 
 
2.6 RNA preparation 
 
 DNase I, RNase-free    (Fermentas, St. Leon-Rot) 
 miRNeasy Mini Kit     (Qiagen, Hilden) 
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 Omniscript RT Kit     (Qiagen, Hilden) 
 peqGOLD TriFast     (PEQLAB, Erlangen) 
 Poly(A) Polymerase    (Ambion, Austin, USA) 
 QIAshredder      (Qiagen, Hilden) 
 RiboLockTM RNase Inhibitor   (Fermentas, St. Leon-Rot) 
 RNase-Free DNase Set    (Qiagen, Hilden) 
 
2.7 Proteins 
2.7.1 Enzymes 
 
Restriction enzymes were purchased from the following companies: 
New England BioLabs (Frankfurt am Main) and Fermentas (St. Leon-Rot) 
 
 Calf Intestine Alkaline Phosohatase (CIAP) (Fermentas, St. Leon-Rot) 
 Platinum® Taq DNA Polymerase   (Invitrogen, Karlsruhe) 
 Proteinase K      (PEQLAB, Erlangen) 
 T4-DNA Ligase     (Fermentas, St. Leon-Rot) 
 Taq DNA Polymerase    (Fermentas, St. Leon-Rot) 
 
2.7.2 Antibodies 
 
 α-BIM (Ab-65): a polyclonal rabbit antibody produced against synthesized 
non-phosphopeptide derived from mouse BIM around the phosphorylation site 
of serine 65 (P-A-Sp-P-G), detects human, mouse and rat BIM 
(Source BioScience AUTOGEN, Calne, UK) 
 anti-digoxigenin-POD, Fab fragments: Fab fragments of an anti-digoxigenin 
antibody from sheep, conjugated with POD, detects digoxigenin    
      (Roche Diagnostics, Mannheim) 
 α-KGF (C-19): a goat polyclonal antibody raised against a peptide mapping at 
the C-terminus of KGF of human origin, detects precursor and mature KGF 
and, to a lesser extent, FGF-10 of human, mouse and rat origin 
(Santa Cruz Biotechnology, Santa Cruz, USA) 
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 α-guinea-pig-POD: POD conjugated antibody, detects IgG from guinea pig 
(personal communication: Janet Brandsma)  
 α-HPV8-E2: a guinea pig antibody raised against a 6x-His-tagged HPV8-E2 
protein, generated in bacteria and purified on a nickel column 
(personal communication: Janet Brandsma)  
 α-MET (Ab-1003): a polyclonal rabbit antibody produced against synthesized 
non-phosphopeptide derived from human MET around the phosphorylation 
site of tyrosine 1003 (V-D-Yp-R-A), detects human, mouse and rat MET 
(Source BioScience AUTOGEN, Calne, UK) 
 α-PDCD4 (EPR3432): a monoclonal rabbit antibody produced against a 
synthetic peptide corresponding to residues near the C-terminus of human 
PDCD4, detects human and mouse PDCD4 
(Epitomics, Burlingame, USA) 
 α-PTEN (Ab-370): a polyclonal rabbit antibody produced against synthesized 
non-phosphopeptide derived from human PTEN around the phosphorylation 
site of serine 370 (D-V-Sp-D-N), detects human, mouse and rat PTEN 
(Source BioScience AUTOGEN, Calne, UK) 
 α-Rb (C-15): a rabbit polyclonal antibody raised against a peptide mapping at 
the C-terminus of Rb of human origin, detects human, mouse and rat Rb p110
      (Santa Cruz Biotechnology, Santa Cruz, USA) 
 
2.8 Staining reagents 
 
 AEC       (Sigma-Aldrich, Steinheim) 
 DAPI       (Merck, Darmstadt) 
 DePeX      (Serva Electrophoresis, Heidelberg) 
 Eosin Y solution     (AppliChem GmbH, Darmstadt) 
 Hematoxylin solution    (Sigma-Aldrich, Steinheim) 
 Kaiser´s glycerol gelatine    (Merck, Darmstadt) 
 Liquid DAB Concentrated Substrate Pack (BioGenex, San Ramon, USA) 
 TSA Biotin System      (PerkinElmer, Waltham, USA) 
 VECTASTAIN Elite ABC Kit (Universal)  (Vector Laboratories, Burlingame, USA) 
 VECTASTAIN Elite ABC Kit (Goat IgG)  (Vector Laboratories, Burlingame, USA) 
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2.9 Buffers and solutions 
 
 AEC stock solution 
Dimethylformamide  5 ml 
AEC    1 pellet 
 
 AEC working solution 
50 mM Na-acetat buffer (pH 5,2) 1ml 
AEC stock solution   67 µl  
H2O2 30 %    2µl 
 
 Ethidium bromide bath 
Ethidium bromide  0,5 µg/ml in H2O 
 
 Sodium phosphate buffer 
NaH2PO4    0,5 M    
Na2HPO4    0,5 M 
    
 
 PBS (Phosphate Buffered Saline) 
NaCl    137 mM 
KCl    2,7 mM 
Na2HPO4    4,3 mM 
KH2PO4    1,4 mM 
 
 Prehybridization-mix 
Formamide   500 µl 
20 X SSC   100 µl 
Sodium phosphate buffer 100 µl
 
  
10 % SDS   50 µl 
0,5 M EDTA   2 µl 
Salmon sperm DNA  10 µg 
H2O    245 µl 
 
 20x SSC (pH 7,0) 
NaCl     3 M 
Na-Citrate    0,3 M 
H2O    add 1 l 
 
 50x TAE buffer (pH 8,0) 
Tris-Acetat   2 M 
EDTA     50 mM 
 
 TE-buffer (pH 8,0) 
Tris    10 mM 
EDTA    1 mM 
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2.10  Chemicals 
 
All chemicals used in this study were purchased from Applichem (Darmstadt), 
Invitrogen (Karlsruhe), Merck (Darmstadt), Roth (Karlsruhe) and Sigma-Aldrich 
(Steinheim) and complied the reagent grade “p.a.”. 
 
 Acetone      (Roth, Karlsruhe) 
 Agarose      (Sigma-Aldrich, Steinheim) 
 Ampicillin      (Sigma-Aldrich, Steinheim) 
 β-Mercaptoethanol     (AppliChem, Darmstadt) 
 Chloroform      (Roth, Karlsruhe) 
 Dimethylformamide     (Fluka, Buchs, Switzerland) 
 DMSO      (AppliChem GmbH,Darmstadt) 
 Ethidium bromide     (Roth, Karlsruhe) 
 Fetal calf serum (FCS)    (Invitrogen, Karlsruhe) 
 Formamide      (Fluka, Buchs, Switzerland) 
 Formaldehyd     (Merck AG, Darmstadt) 
 Glucose      (Roth, Karlsruhe) 
 Glycin       (Roth, Karlsruhe) 
 Glycogen      (Sigma-Aldrich, Steinheim) 
 Isoamylalkohol     (Roth, Karlsruhe) 
 Mixer Mill 301     (Retsch, Haan) 
 Polyethylene glycol     (Sigma-Aldrich, Steinheim) 
 Pepsin       (Sigma-Aldrich, Steinheim) 
 Phenol      (Roth, Karlsruhe) 
 RNALater      (Qiagen, Hilden) 
 Sybr Green I      (Sigma-Aldrich, Steinheim) 
 
Plastic goods were purchased from Eppendorf (Hamburg), Falcon BD (Heidelberg), 
Greiner (Solingen), Sarstedt (Nümbrecht) and TPP (Trasadingen, Switzerland) 
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2.11  Media 
2.11.1 Media for cultivation of bacteria 
 
 LB-medium (Luria-Bertani-medium) pH 7,2 (Difco, Detroit, USA) 
Bacto tryptone  10 g/l 
Bacto yeast-extract  5 g/l 
NaCl     8 g/l 
  H2O    add 1 l 
  autoclaved for 20 min at 121°C 
Medium was cooled down to 50°C before ampicillin wa s added in a final 
concentration of 100 µg/ml (optional) 
 
 LB Agar pH 7,2     (Difco, Detroit, USA) 
  Bacto tryptone  10 g/l 
  Bacto yeast-xtract   5 g/l 
  NaCl     8 g/l 
  Bacto agar   15 g/l 
H2O    add 1 l 
autoclaved for 20 min at 121°C 
Agar was cooled down to 50°C before ampicillin was added in a final 
concentration of 100 µg/ml (optional) and poured into petri dishes 
 
 TSB-medium (Transformation and Storage Medium) 
PEG (MW=3350)  30 mM 
DMSO   5 % 
MgCl2    10 mM 
MgSO4   10 mM 
LB-medium   add 1 l 
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2.11.2 Media for cultivation of eukaryotic cells 
 
 Dulbecco´s modified Eagle´s medium (DMEM) (Invitrogen, Karlsruhe) 
with GlutamaxTM, 4500 mg/l glucose 
without sodium pyruvate 
FCS    10 %  (Invitrogen, Karlsruhe) 
Penicillin   100 units/ml (Invitrogen, Karlsruhe) 
Streptomycin  100 µg/ml (Invitrogen, Karlsruhe) 
 
 Freezing medium 
DMSO   10%  (Invitrogen, Karlsruhe) 
FCS    90%  (Invitrogen, Karlsruhe) 
 
 PBS       (Invitrogen, Karlsruhe) 
 Trypsin/EDTA     (Invitrogen, Karlsruhe) 
 
2.11.3 Antibiotics for cell culture 
 
 G418-Sulfat       
An aminoglycoside antibiotic that blocks polypeptide synthesis by inhibiting the 
elongation step in both prokaryotic and eukaryotic cells. Resistance to G418 is 
conferred by the neomycin gene.   (PAA, Pasching, Austria) 
 
2.12  Miscellaneous 
 
 Axiophot microscope    (Zeiss, Göttingen) 
 5-Liner needles     (Bortech, Wuppertal) 
 Cryotome Leica CM3000    (Leica, Wetzlar) 
 Depilatory cream     (Balea, Karlsruhe) 
 Fluorescence microscope Leica DMI 6000 B (Leica, Wetzlar) 
 LightCycler System     (Roche Diagnostics, Mannheim) 
 Punch biopsy tool     (pfm, Köln) 
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 Steel balls      (Retsch, Haan) 
 T3-Thermocycler     (Biometra, Göttingen) 
 Tape       (Tesa, Hamburg) 
 Tattoo machine Rotary 12000PL   (Bortech, Wuppertal) 
 Tissue-Tek O.C.T. Compound   (Sakura Finetek, Heppenheim) 
 
2.13  Mice 
 
Line Description Reference 
FVB/N wt wildtype, breeding Charles River, 
Germany, Sulzfeld 
FVB/N HPV8-CER transgenic for the early genes of 
HPV8 
Schaper et al., 2005 
FVB/N HPV8-E2 transgenic for HPV8-E2 Pfefferle et al., 2008 
FVB/N HPV8-E6 transgenic for HPV8-E6 Marcuzzi et al., 
2009 
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3 Methods 
 
3.1 Bacterial culture 
3.1.1 Production of competent bacteria for transformation 
 
Transformation competent E.coli XL1 Blue were produced as described in the 
protocol from Chung and Miller (1988). 100 ml LB-medium was inoculated with 2,5 ml 
of a fresh bacterial culture and incubated at 37°C under agitation until an OD600 of 0,5 
was reached. Bacteria were put on ice for 10 min followed by centrifugation for 10 
min at 3000 g at 4°C. The pellet was resuspended in  5 ml ice-cold TSB-medium and 
put again on ice for 10 min. The now competent bacteria were aliquoted in prechilled 
tubes, shock frozen in liquid nitrogen and stored at -80°C. The efficiency of the 
competent bacteria was tested by transforming 100 µl bacteria with 1 ng plasmid. 
With the help of the number of formed colonies the efficiency of the bacteria could be 
calculated when transformed with 1 µg DNA. Normally the efficiency was between 
5x103 and 3x106 colonies per microgram DNA. 
 
3.1.2 Transformation of competent bacteria 
 
Transformation of competent E.coli XL1 bacteria was done by pipetting DNA (ca. 100 
ng) to 100 µl bacteria and incubating on ice for 30 min. Afterwards bacteria were 
subjected to heat shock at 42°C for 45 seconds, the n shifted back on ice for 3 min. 
Subsequently 100 µl LB-medium with 20 mM glucose was added and after 1 h at 
37°C under agitation, bacteria were plated onto amp icillin LB-agar plates and 
incubated over night at 37°C. 
 
3.1.3 Culturing bacteria for plasmid isolation 
 
All plasmids in this study contain an ampicillin resistance gene. Therefore selection of 
bacteria transformed with a plasmid could be accomplished by adding 100 µg/ml 
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ampicillin to LB-medium and agar plates. For analytic plasmid isolation 5 ml LB-
medium was inoculated with bacteria in a 13 ml PE-tube (Sarstedt, Nümbrecht) and 
was put into a rotation incubator overnight at 37°C  under agitation. For preparative 
plasmid isolation bacterial cultures were grown in 200 ml LB-medium in an 
Erlenmeyer flask and were put into a rotation incubator at 37°C under agitation 
overnight. 
 
3.1.4 Bacterial glycerol stock 
 
From a dense bacterial culture 800 µl were mixed with 200 µl glycerol and was stored 
at -80°C. 
 
3.2 Cell culture 
 
All cell lines listed here were adherent cell lines, cultivated at 37°C, 6 % CO 2 and 80-
90% humidity with DMEM containing 10 % FCS, 100 units/ml penicillin and 100 µg/ml 
streptomycin. All operations with these cell lines were done under a laminar flow. 
 
3.2.1 Cultivation of cell lines 
 
Cells were passaged constantly when they reached a density of about 90 % at most, 
by washing with PBS following Trypsin/EDTA treatment. As soon as the cells 
detached from the bottom of the flask they were resuspended in fresh medium and 
seeded at the desired density in a new tissue culture flask. 
 
3.2.2 Freezing of cell lines 
 
For long term storage cells were grown in 150 cm2 tissue culture flask until they 
reached a density of about 90%. Then the cells were washed with PBS and detached 
with 5 ml Trypsin/EDTA and mixed with 9 ml of the appropriate cell culture medium. 
After centrifugation at 300 g for 5 min the pellet was resuspended in 4,5 ml freezing 
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medium, aliquoted into 1,5 ml in freezing vials (Nunc, Langenselbold), and stored at -
80°C. 
 
3.2.3 Cell counting using a hemocytometer 
 
The cell count of a cell suspension was determined by a hemocytometer with a cover 
slip attached. The hemocytometer is divided in nine main squares which form a 
bigger square. It has a depth of 0,1 mm and each main square has an area of 1 mm2. 
An aliquot of a well mixed suspension was pipetted to the edge of the cover slip and 
was sucked under the cover slip due to capillary power. Cells were counted in the 
four squares of the corners via microscope. The mean value of the four squares 
multiplied with 104 equals the cell count in one ml of the cell suspension. 
 
3.2.4 Transfection of cells with Lipofectamine 2000 
 
SiRNA transfections were done with “Lipofectamine 2000” (Invitrogen, Karlsruhe). 
For this purpose 3 x 104 cells were seeded in a 24-well and incubated overnight at 
37°C. The following day cells were washed once with  PBS and fresh medium without 
antibiotics was added. Unless otherwise noted 30 picomole siRNA were added to 50 
µl medium without antibiotics and FCS and 1,5 µl “Lipofectamine 2000” was added to 
another 50 µl medium without antibiotics and FCS. After 5 min incubation at RT the 
diluted “Lipofectamine 2000” was added to the diluted siRNA and incubated for 20 
min at RT. The siRNA-Lipofectamine 2000 complexes were then added to the well 
containing cells. 
 
3.2.5 Creation of the stable cell lines HaCaT-pLXSN8-E6, PM1-pLXSN 
and PM1-pLXSN8-CER via transduction 
 
One day before transduction 2 x 105 HaCaT and PM1 cells were seeded in a cell 
culture dish (6 cm). The next day cells were incubated with 2 ml DMEM without 
additives but with 5 µg/ml polybrene (Sigma-Aldrich, Steinheim) for 10 min at 37°C. 
Two ml retroviral supernatant pLXSN8-E6, pLXSN or pLXSN8-CER (virus particles 
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provided by Dr. Baki Akgül) with 2 ml DMEM without additives but with 5 µg/ml 
polybrene (Sigma) was added to the cell culture dish. The cells were centrifuged at 
300 g for 1h at RT, washed twice with PBS and finally incubated with 2 ml normal 
cultivation media for 48 h at 37°C. Since pLXSN enc odes the neomycin resistance 
gene, selection of transduced cells was performed by adding G418 (PAA, Pasching, 
Austria) to the media in a final concentration of 500 µg/ml. As a negative control 
HaCaT and PM1 cells without transduction were also incubated with media 
containing G418 (PAA) in a final concentration of 500 µg/ml. After 48 h cells reached 
a confluence of about 80 % and were splitted in a 75 cm2 tissue flask. Selection 
media was exchanged with normal cultivation media when all control cells were 
dead, usually after one week. Transcription of stably transduced DNA was verified by 
qRT-PCR (3.3.8). 
 
3.3 DNA methods 
3.3.1 DNA standard methods 
 
The methods mentioned below were performed according to the protocols from 
Sambrook et al. (1989) 
 
 DNA digestion by restriction nucleases 
 Dephosphorylation of 5‘-end DNA fragments by alkaline phosphatase 
 Ligation of DNA by T4-Ligase 
 Phenol/Chloroform extraction of DNA 
 Ethanol precipitation of DNA 
 
3.3.2 Determination of DNA concentration 
 
DNA concentration and degree of purity was determined spectrophotometrically at a 
wavelength of 260 nm and 280 nm using a NanoDrop®ND-1000 UV/Vis spectral 
photometer (PEQLAB, Erlangen).  
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3.3.3 Plasmid preparation 
 
Plasmid isolation for analytic and preparative was done using kits from Qiagen 
(Hilden) “QIAprep Spin Miniprep Kit, QIAprep 8 Miniprep Kit”, Invitrogen (Karlsruhe) 
“PureLink™ HiPure Plasmid Filter Maxiprep Kit” and Fermentas (St. Leon-Rot) 
“GeneJET™ Plasmid Miniprep Kit” according to the manufacturer’s protocol. These 
kits base upon the extraction method from Birnboim and Doly (1979) and the 
property of DNA to bind on anion exchanger columns. 
 
3.3.4 Agarose gel electrophoresis 
 
Agarose gels were prepared by dissolving 0,5 g – 2,5 g of agarose (Sigma-Aldrich, 
Steinheim) in 100 ml of 1X TAE buffer, boiled and poured into a gel slide. 6x 
(Orange) DNA Loading Dye (Fermentas, St. Leon-Rot) was added to the DNA 
samples to a final concentration of 1x. Samples and DNA markers were loaded and 
electrophoresed in 1X TAE buffer. DNA was visualized by UV light. 
 
3.3.5 Isolation of DNA from agarose gels 
 
Following electrophoretic separation, the desired DNA band was cut out from the 
agarose gel with a scalpel under long-wave UV (365 nm). DNA was isolated from 
agarose gel with “QIAEX II Gel Extraction Kit” (Qiagen, Hilden) as described in the 
manufacturer’s protocol. 
 
3.3.6 Isolation of genomic DNA from mouse tails for genotyping 
 
After marking the mouse ear, 5 mm of the mouse tail was cut off. Genomic DNA was 
isolated from this piece of tail with the “DirectPCR Lysis Reagent (Tail)” (PEQLAB, 
Erlangen) and “Proteinase K” (PEQLAB, Erlangen) according to the manufacturer´s 
protocol. The isolated genomic DNA was tested for the presence of the transgene by 
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PCR (3.3.7). In HPV8-CER mice the DNA was tested for HPV8-E6. In HPV8-E2 and -
E6 mice the DNA was tested for the respective transgene. 
 
3.3.7 Polymerase chain reaction (PCR) 
 
Amplification of defined DNA fragments was done by the PCR method (Mullis and 
Faloona 1987). The reaction was performed using 50 - 100 ng DNA as template in a 
total volume of 20 µl containing 1 unit Taq DNA Polymerase and the associated 
buffer with (NH4)2SO4 (Fermentas, St. Leon-Rot), 1 mM MgCl2, 5 % DMSO 
(Applichem, Darmstadt) 0.5 µM forward and backward primer each and 0.2 mM 
deoxynucleotide triphosphates each (Fermentas, St. Leon-Rot). The reaction was 
carried out in a thermocycler. The cycling protocol conditions were 3 min at 94°C, 
followed by 30 cycles of 30 second at 94°C, 30 seco nds at Tann and 60 seconds at 
72°C. A final extension step was carried out at 72° C for 5 min, before samples were 
cooled at 4°C. 
 
3.3.8 Quantitative real-time polymerase chain reaction (qRT-PCR) 
 
mRNA and miRNA levels were measured by qRT-PCR using the LightCycler System 
(Roche Diagnostics, Mannheim). Two microliters of a 1:10 dilution of cDNA 
(generated as described in 3.4.5 or 3.4.6) were used in a total volume of 20 µl 
containing 1.25 units Platinum Taq Polymerase and the associated buffer (Invitrogen, 
Karlsruhe), 4 mM MgCl2, 1.6 µl of a 1:1000 dilution of SybrGreen I (Sigma-Aldrich, 
Steinheim), 5 % DMSO (Applichem, Darmstadt) 0.5 µM forward and backward primer 
each, 500 ng/µl non-acetylated bovine serum albumin (Fermentas, St. Leon-Rot) and 
0.2 mM deoxynucleotide triphosphates each (Fermentas, St. Leon-Rot). Samples 
were analyzed in duplicate together with a cDNA or plasmid dilution series of the 
plasmids described in 2.3.5, which was used to generate a standard curve. The 
cycling protocol conditions were 60 seconds at 95°C , followed by 40 cycles of 1 
second at 95°C (20°C/s), 5 seconds at T ann. (20°C/s), and 15 seconds at 72°C 
(20°C/s). Fluorescence was measured once per cycle at the end of the elongation 
step. Subsequently a melting curve protocol was carried out consisting of 15 seconds 
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at 95°C, followed by 20 seconds at 70°C (20°C/s) an d 1 second at 95°C (0,2°C/s). 
Fluorescence was measured continuously during heating to 95°C. Finally samples 
were cooled down to 40°C for 10 seconds. All mRNA l evels were normalized to the 
total RNA input used for reverse transcription, HPRT1 or β-actin. All miRNA levels 
were normalized to miRNA-127. 
 
3.3.9 DNA Sequencing 
 
DNA sequencing was performed in the CMMC (Center for Molecular Medicine, 
University of Cologne) by an automated method (Sanger et al. 1977) with 
fluorescence-labeled oligonucleotides. For this purpose 3 - 10 pmol sequencing 
oligonucleotides (2.3.1.3) and 250 - 350 ng DNA were used in the sequencing 
reaction. Sequence analysis was carried out with the program “Chromas Lite” 
(Technelysium Pty Ltd, Tewantin, Australia). 
 
3.3.10 Oligonucleotide labeling for in situ hybridization 
 
Labeling of oligonucleotides for in situ hybridization probes was done with “DIG 
Oligonucleotide 3´-End Labeling Kit” (Roche Diagnostics, Mannheim). For this 
purpose 100 pmol in situ hybridization oligonucleotide (2.3.1.5) was adjusted with 
RNase-free H2O to a total volume of 10 µl. The labeling reaction was carried out as 
described in the manufacturer´s protocol. 
 
3.4 RNA methods 
3.4.1 Total RNA Isolation 
 
Total RNA isolation from cells or mouse skin was done by using either “miRNeasy 
Mini Kit” (Qiagen, Hilden) or “peqGOLD TriFast” (PEQLAB, Erlangen) as described in 
the manufacturer´s protocol, respectively. 
Cells were plated in 6- or 24-well plates for RNA Isolation. At the desired point in time 
the medium was aspirated and cells were taken up in “lysis buffer” (Qiagen) or 
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“peqGOLD TriFast” (PEQLAB). When using “miRNeasy Mini Kit” (Qiagen) cells were 
further homogenized by “QIAshredder” (Qiagen, Hilden) and DNA digestion was 
performed on column using “RNase-Free DNase Set” (Qiagen, Hilden). When using 
“peqGOLD TriFast” (PEQLAB), DNA digestion was done after completion of RNA 
isolation (3.4.3). 
For RNA isolation from mouse skin, biopsy samples were transferred from RNALater 
(Qiagen, Hilden) into a tube containing a steel ball and “lysis buffer” (Qiagen) or 
“peqGOLD TriFast” (PEQLAB). Afterwards biopsies were homogenized in a swing 
mill (Mixer Mill 301, Retsch, Haan) at 30 Hz for 3 min. For full homogenization of the 
mouse skin, tubes were turned around and shaken for another 3 min at 30 Hz. When 
using “miRNeasy Mini Kit” (Qiagen) DNA digestion was performed on column using 
RNase-Free DNase Set (Qiagen). When using “peqGOLD TriFast” (PEQLAB), DNA 
digestion was done after completion of RNA isolation (3.4.3). For all preparations 
RNA was dissolved in 30-50 µl RNase-free H2O. 
 
3.4.2 Determination of RNA concentration 
 
RNA concentration and degree of purity was determined spectrophotometrically at a 
wavelength of 260 nm and 280 nm using a NanoDrop®ND-1000 UV/Vis spectral 
photometer (PEQLAB, Erlangen). 
 
3.4.3 DNA digestion 
 
When using “peqGOLD TriFast” (PEQLAB, Erlangen), DNA digestion was done with 
“DNase I, RNase-free” (Fermentas, St. Leon-Rot). One microgram total RNA (100 ng 
total RNA if RNA was isolated from cells in a 24-well plate) was treated with 1 unit 
DNase I, 1 µl 10X reaction buffer with MgCl2 and adjusted to a total volume of 10 µl 
with RNase-free H2O. DNase digestion was completed after 30 min at 37°C and was 
stopped by adding 1 µl 25 mM EDTA and incubating at 65°C for 15 min. 
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3.4.4 Polyadenylation of miRNAs 
 
Polyadenylation of miRNAs was adapted from Shi and Chiang (2005). Total RNA 
was isolated as described in 3.4.1 and DNA was digested during isolation or as 
described in 3.4.3. One microgram of DNA-free RNA was polyadenylated in a total 
volume of 20 µl containing 2 units Poly(A) Polymerase (Ambion, Austin, USA), 4 µl of 
the associated buffer, 2.5 mM MnCl2 and 1 mM ATP (Fermentas, St. Leon-Rot) for 1 
h at 37°C. The enzyme was inactivated at 75°C for 1 0 min and buffer was exchanged 
by ethanol precipitation. 
 
3.4.5 Reverse transcription of mRNAs 
 
Total RNA was isolated as described in 3.4.1 and DNA was digested during isolation 
or as described in 3.4.3. One microgram of DNA-free RNA (100 ng total RNA if RNA 
was isolated from cells of a 24-well plate) was reverse transcribed using “Omniscript 
RT Kit” (Qiagen, Hilden) in a total volume of 20 µl with 10 µM random nonamers (TIB 
MOLBIOL, Berlin), 1 µM oligo-dT23-primer (Sigma-Aldrich, Steinheim) and 10 units 
RiboLockTM RNase Inhibitor (Fermentas, St. Leon-Rot). The reaction was carried out 
at 37°C for 1 h, afterwards reverse transcriptase w as inactivated at 95°C for 10 min. 
 
3.4.6 Reverse transcription of miRNAs 
 
Reverse transcription of miRNAs was adapted from Shi and Chiang (2005). Purified 
polyadenylated DNA-free RNA (3.4.4) was reverse transcribed as described in 3.4.5, 
but instead of random nonamers and oligo-dT23-primer 1.5 µM miRNA adaptor was 
used and the reaction was carried out for 2 h at 37°C. 
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3.4.7 In situ hybridization (ISH) 
 
Deparaffinization of 4 µm thick tissue sections was done by incubation in xylene two 
times for 5 min. Samples were hydrated through a descending alcohol series (100%, 
90%, 70%; 5 min each). Sections were then incubated in 0.5% SDS in PBS for 15 
min at RT, following two washes with dest. H2O. Further incubation steps were 
performed in a humid chamber to prevent drying-out. Permeabilization of tissue was 
reached by treating the sections with 0,2% pepsin (Sigma-Aldrich, Steinheim) in 0.2 
M HCl for 15 min at 37°C and stopped by incubating two times in 0,1 M Glycine 
(Roth, Karlsruhe) in PBS for 3 mines at RT. After two washes with PBS, DNA 
digestion was performed with 50 units/ml DNase (Fermentas, St. Leon-Rot) in the 
associated buffer for 1 h at 37°C, following a shor t wash step with PBS. Endogenous 
peroxidases were inactivated by incubation in 3% H2O2 in Methanol for 20 min. 
Afterwards sections were washed two times with dest. H2O and two times with 2X 
SSC, 3 min each. The prehybridization-mix was heated for two min. at 90°C and put 
on the slides, which then were put on a heat plate at 90°C for 2 min. After 1-2 h 
incubation at RT the prehybridization-mix was exchanged with 90°C preheated 
prehybridization-mix with 5 pmol digoxigenin-labeled probe (3.3.10)3.3.10. The slides 
were put on a heat plate at 90°C for 2 min and incu bated overnight at RT. Next day 
slides were washed two times with 2X SSC for 15 min at 37°C, one time with 1X SSC 
for 15 min at 37°C and one time with 0.5X SSC for 1 5 min at 37°C. Detection of 
digoxigenin-labeled probes was done with anti-digoxigenin-POD Fab fragments 
(Roche Diagnostics, Mannheim) in a 1:100 dilution and TSA Biotin System 
(PerkinElmer, Waltham, USA) according to the manufacturer’s protocol. Afterwards 
AEC staining was performed by pipetting AEC working solution on the slides. 
Sections were counterstained with hematoxilin (Sigma-Aldrich, Steinheim) and 
embedded with Kaiser´s glycerol gelatine (Merck, Darmstadt). 
 
3.4.8 MiRNA microarray 
 
Five microgram total RNA (3.4.1) from healthy skin of one FVB/N wt and one HPV8-
CER mouse was analyzed in a comparative µParaflo microarray by LC Sciences 
(Houston, USA) based on the Sanger mirBase: release 8.2. 
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3.5 Protein methods 
3.5.1 Immunohistochemistry (IHC) 
 
Deparaffinization of 4 µm thick tissue sections was done by incubation in xylene two 
times for 5 min. Samples were hydrated through a descending alcohol series (100%, 
90%, 70%; 5 min each) and endogenous peroxidases were inactivated by incubation 
in 3% H2O2 in Methanol for 20 min. Antigen unmasking was performed by boiling the 
tissue sections in 10 mM citric buffer in a pressure cooker for 4 min in a microwave. 
Further incubation steps were performed in a humid chamber to prevent drying-out. 
HPV8-E2 staining: After blocking unspecific antigen sites with 20% FCS in PBS for 1 
h, samples were incubated with primary antibody α-HPV8-E2 in 2  FCS in PBS for 90 
min followed by three washes with PBS. Incubation with secondary antibody α-
guinea-pig-POD diluted in 2% FCS in PBS was done for 1 h, following three washes 
with PBS. 
KGF, MET, PDCD4, PTEN, and Rb staining: Blocking of unspecific antigen sites was 
done with 50% horse serum in PBS for 30 min, for α-KGF antibody 50% rabbit serum 
in PBS was used. Incubation of primary antibody was done in 2% horse serum for 90 
min, α-KGF antibody was diluted in 2% rabbit serum in PBS, followed by three 
washes with PBS. Detection of primary antibody was done with the “VECTASTAIN 
Elite ABC Kit (Universal)” (Vector Laboratories, Burlingame, USA), for α-KGF 
antibody “VECTASTAIN Elite ABC Kit (Goat IgG)” (Vector Laboratories) was used as 
described in the manufacturer’s protocol. 
DAB staining was performed with the “Liquid DAB Concentrated Substrate Pack” 
(BioGenex, San Ramon, USA). Sections were counterstained with hematoxilin and 
dehydrated with an ascending alcohol series (70%, 90%, 100%; 3 min each). After a 
final incubation in xylene for 5 min sections were embedded with mounting medium 
“DePeX” (Serva Electrophoresis, Heidelberg). 
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3.6 Experimental operations in mice 
 
Generally, mice were anesthetized with Ketamine-hydrochloride (Sigma-Aldrich, 
Steinheim) and Xylazine-hydrochloride (Sigma-Aldrich, Steinheim) and shaved with 
an electric shaver (Wella, Karlsruhe) before any treatment. 
 
3.6.1 UV-irradiation of mouse skin 
 
Dorsal caudal UV-irradiation was performed at an age of 6-12 weeks. Mice were 
either irradiated with 10 J/cm2 UVA and 1 J/cm2 UVB or with 10 J/cm2 UVA alone or 
0,36 J/cm2 UVB alone on a 4 cm2 sized area as reported before (Pfefferle et al. 2008; 
Marcuzzi et al. 2009). 
3.6.2 Mechanical irritation of mouse skin (tape-stripping, tattooing) 
 
After shaving, mouse skin was treated with depilatory cream (Balea, Karlsruhe) on a 
4 cm2 sized area at an age of 6-12 weeks. For tape stripping experiments mice were 
treated by attaching and detaching 15 times a new piece of tape (Tesa, Hamburg) in 
the depilated area. For tattooing experiments an area of mouse skin was laid on top 
of another, in this way both dermis matched each other. 3 lines of about 1 cm length 
were tattooed on top of each other in the depilated area, each in 5 seconds, thereby 
penetrating both skin layers. Tattooing was performed using a “Rotary 12000PL” 
tattoo machine with 5-Liner needles (Bortech, Wuppertal). The machine was run by 
17,5 V, resulting in 500 pinholes per second. 
 
3.6.3 Taking skin biopsies 
 
Mouse skin samples were either taken by punch biopsies (4 mm diameter, pfm, Köln) 
or by scissors. For RNA-analysis samples were stored at -20°C in RNALater 
(Qiagen, Hilden) according to the manufacturer’s protocol. For IHC and ISH 
experiments mouse skin samples were formalin-fixed and embedded in paraffin. For 
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experiments with siRNA-control-fluorescein, samples were embedded into Tissue-
Tek O.C.T. Compound (Sakura Finetek, Heppenheim) and stored at –20°C. 
3.6.4 Sectioning mouse skin samples with a cryotome 
 
Mouse skin samples embedded into Tissue-Tek O.C.T. Compound (Sakura Finetek, 
Heppenheim) were cut with a Leica CM3000 cryotome (Leica, Wetzlar) into 5 µm 
thick sections and transferred on a slide. Coverslips were mounted on the slides with 
Kaiser´s glycerol gelatine (Merck, Darmstadt). 
 
3.6.5 Paraffin embedding and sectioning of mouse skin samples 
 
Formalin-fixed mouse skin samples were embedded and cut into 4 µm thick sections 
at the dermatology of the University Hospital of Cologne. 
 
3.6.6 Cell nucleus staining of mouse skin sections with DAPI 
 
Cell nucleus staining of mouse skin sections was performed with DAPI (Merck, 
Darmstadt) as described in the manufacturer’s protocol. 
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4 Results 
 
4.1 Papilloma growth and HPV8 oncogene expression in HPV8-
CER mice 
 
4.1.1 Papilloma development is induced after UVA/B-irradiation 
 
The simulation of sunburn by a single UVA/B-dose (10 J/cm2
 
UVA and 1 J/cm2 UVB) 
led to papilloma formation within three weeks in HPV8-CER mice, while the skin of 
FVB/N wt mice healed completely within this time period (Marcuzzi 2006). In order to 
analyze the influence of UVA/B-irradiation on transgene expression levels during 
papilloma development, kinetics of oncogene expression were determined after 
UVA/B-irradiation of HPV8-CER mice.  
Figure 4 shows typical alterations of the skin of an HPV8-CER mouse over a 30 day 
period after UVA/B-irriadiation. Six hours after irradiation only a slight redness was 
visible, which was distinct four days after irradiation indicating sunburn. The 
irradiated area swelled and became hairless on day seven after irradiation. Papilloma 
development was first detectable on day twelve. The papillomas grew larger over the 
following observation period. 
 
 
 
 
 
 
 
 
 
  
Figure 4: Development of papilloma
The back of the mouse was shaved and 
sized skin area. Pictures show treated skin areas at different points in time
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Figure 5: Perpetuation of enhanced mK14 and HPV8-E6 expression in HPV8-CER mice after 
UVA/B-irradiation. 
(a) Diagram of the two different skin punch protocols. Skin punch biopsies were either taken at a 
single point in time (left mouse, e.g. 2d) or at four different points in time from the same mouse out of 
the irradiated area (yellow box) (middle mouse 6h, 4d, 7d, 12d; right mouse 12d, 18d, 24d, 30d). 
Additionally, skin punch biopsies were taken at the end of the respective time period out of the non-
irradiated area (b) The backs of shaved HPV8-CER and FVB/N wt mice were irradiated with 10 J/cm2 
UVA and 1 J/cm2 UVB on a 4 cm2 sized area. Skin samples were taken at different points in time after 
UVA/B-irradiation from irradiated and non-irradiated skin areas. HPV8-E6 and mK14 mRNA 
expression levels were measured in one microgram of reverse transcribed total cellular RNA by qRT-
PCR. The mRNA level in irradiated skin was normalized to the level of the respective mRNA in 
untreated skin of the same mouse. The mean expression ratio of mK14 in HPV8-CER mice (black 
solid lines), mK14 in FVB/N wt mice (gray lines) and HPV8-E6 in HPV8-CER mice (black dashed 
lines) is plotted against time. Error bars represent the standard deviation. (c) Table shows number of 
analyzed samples per point in time from different mice. 
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Generally, a stronger mean mK14 expression in HPV8-CER mice than in FVB/N wt 
mice after UVA/B-irradiation was observed (Figure 5b). Induction of mK14 expression 
as well as HPV8-E6 was already seen one day after UV-irradiation in HPV8-CER 
mice. Between day two and day twelve after UVA/B-irradiation enhanced mK14 
expression was measured in both mouse strains. In FVB/N wt mice mK14 expression 
returned to an almost basal level along with healing of the irradiated skin during the 
following observation period. In contrast, mK14 expression as well as HPV8-E6 
expression persisted on a high level in HPV8-CER mice at all following points in time. 
 
4.1.3 Expression ratio of HPV8-E2, -E6 and -E7 in HPV8-CER mice 
 
The HPV8 oncogenes E2, E6 and E7 are all under the control of the hK14-promoter 
in HPV8-CER mice. Therefore it was speculated that these genes are equally 
transcribed. To check this hypothesis for further examinations, the transcript levels of 
HPV8-E2, -E6, and -E7 were measured in non-lesional skin samples from six HPV8-
CER mice by qRT-PCR and were correlated with each other. 
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Figure 6: HPV8-E2, -E6 and -E7 are equally expressed in HPV8-CER mice. 
HPV8-E2, -E6 and -E7 mRNA levels were measured in one microgram of reverse transcribed RNA 
from non-lesionsl skin samples of six HPV8-CER mice by qRT-PCR and normalized to the mRNA 
level of HPRT1. 
 
All three transgenes (E2=0.99; E6=1.06; E7=0.97) showed nearly the exact same 
transcript level in the skin of HPV8-CER mice (Figure 6). Therefore it can be 
assumed that all three transgenes are equally expressed from the hK14-promoter. 
This means that the expression of any of these three transgenes mirrors the 
expression of the others.  
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4.1.4 Papilloma growth was paralleled by enhanced HPV8 protein levels 
 
To study, whether the increase of transgene mRNA levels in the skin of HPV8-CER 
mice is also reflected at the protein level and to characterize the HPV8-oncoprotein 
positive epidermal layers, sections of UVA/B-irradiated and non-irradiated HPV8-
CER skin were immunohistochemically stained for HPV8-E2. As reference for 
changes in normal mouse skin, the histology of UVA/B-irradiated FVB/N wt skin was 
also documented by HE-staining. The antibody against HPV8-E2 showed no cross-
reactivity on FVB/N wt sections (data not shown). 
Untreated HPV8-CER skin revealed a clear but faint HPV8-E2 signal in the epidermis 
(Figure 7, left column) whereas, in line with RNA data, E2 protein expression 
increased already one day after UVA/B-irradiation. Both an increased number of 
transgene expressing cells and more intense staining were observed. In the progress 
of papilloma development (UV 2d – UV 10d) more epidermal cell layers emerged, all 
being HPV8-E2 protein positive. The enhanced protein expression was maintained 
over the whole observation period ending on day 24 after UVA/B-irradiation, when a 
papilloma with multiple epidermal cell layers and horn pearls had already developed. 
Histology of UVA/B-irradiated FVB/N wt mouse skin showed an only slightly thinner 
epidermis than HPV8-CER mouse skin until day seven after UVA/B-irradiation 
(Figure 7, right column). However, about ten days after irritation, the epidermis of 
control FVB/N wt mice started to regress to its normal status with one or two cell 
layers. In conclusion these results demonstrate that enhanced expression levels of 
HPV8 oncoprotein are paralleled by papillomatosis in HPV8-CER mice.  
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Figure 7: Immunohistochemical staining for HPV8-E2 in HPV8-CER skin sections revealed 
enhanced HPV8-E2 protein expression after UVA/B-irradiation. 
The backs (4 cm2) of shaved HPV8-CER and FVB/N wt mice were irradiated with 10 J/cm2 UVA and 1 
J/cm2 UVB. For each point in time biopsies were taken out of the irradiated skin of two mice. Skin 
biopsies were also taken from two non-irradiated HPV8-CER and FVB/N wt mice. Formalin-fixed and 
paraffin embedded samples were cut into sections. HPV8-CER sections were stained against HPV8-
E2 and counterstained with hematoxylin. FVB/N wt sections were H&E stained. Magnification: 400x. 
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4.1.5 UVA/B-irradiated HPV8-E2 and -E6 mice with enhanced transgene 
mRNA expression developed papillomas 
 
As demonstrated at our institute before, HPV8-E6 mice perfectly mirror the HPV8-
CER mouse phenotype, including rate and prevalence of spontaneous and UVA/B-
induced papillomatosis (Marcuzzi 2006). Therefore, persistently enhanced 
expression levels of mK14 and accordingly of transgenes were expected for HPV8-
E6 mice. In contrast, for HPV8-E2 mice, which present a lower papilloma penetrance 
(Pfefferle et al. 2008), perpetuation of enhanced mK14 expression was only expected 
in some cases. To test this, skin punch biopsies from three HPV8-E2 and three -E6 
mice were taken 12, 18, 24 and 30 days after UVA/B-irradiation. 
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Figure 8: Papilloma growth is accompanied by enhanced mK14 expression in HPV8-E6 and E2 
mice after UVA/B-irradiation. 
The backs of shaved HPV8-E2 and E6 mice were irradiated with 10 J/cm2 UVA and 1 J/cm2 UVB on a 
4 cm2 sized skin area. Skin punch biopsies were taken at different points in time after UVA/B-
irradiation out of the irradiated and non-irradiated skin. MK14 mRNA expression levels were measured 
in one microgram of reverse transcribed total cellular RNA by qRT-PCR. The mK14 level in irradiated 
skin was normalized to the mK14 level in untreated skin of the same mouse. (a) The mean mK14 
expression ratio of three HPV8-E6 mice is plotted against time after irradiation. Error bars represent 
the standard deviation. (b) The mK14 expression ratio of three HPV8-E2 mice is plotted against time. 
 
For HPV8-E6 mice enhanced transgene expression levels were measured and 
papilloma development was observed as seen for HPV8-CER mice (Figure 8a). 
However, only one HPV8-E2 mouse (1) developed papillomas and showed 
enhanced mK14 expression levels for all examined points in time (Figure 8b). The 
two other HPV8-E2 mice (2 and 3) did not develop papillomas and showed always 
lower mK14 expression levels compared to mouse 1. 
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4.1.6 UVB-irradiation alone is sufficient to induce transgene expression 
in HPV8-CER mice 
 
It was previously shown that 0,36 J/cm2 UVB-irradiation alone is sufficient to induce 
papillomatosis in HPV8-CER mice, while 10 J/cm2 UVA-irradiation does not lead to 
papilloma development (Marcuzzi 2006). To check, if these two wavelengths also 
differ in their ability to stimulate transgene expression, mK14 levels were measured 
in three UVA and three UVB irradiated HPV8-CER and FVB/N wt mice. 
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Figure 9: UVB-irradiation alone led to enhanced mK14 expression in HPV8-CER and FVB/N wt 
mice, while UVA-irradiation did not. 
The backs (4 cm2) of three shaved HPV8-CER and three shaved FVB/N wt mice were either UVA-
irradiated (10 J/cm2) or UVB-irradiated (0,36 J/cm2). Skin punch biopsies were taken twelve days after 
UVA- or UVB-irradiation out of the irradiated and non-irradiated skin. MK14 mRNA expression levels 
were measured in one microgram of reverse transcribed total cellular RNA by qRT-PCR. The mK14 
level in irradiated skin was normalized to the mK14 level in untreated skin of the same mouse. Bars 
represent the mean mK14 expression ratio of three FVB/N wt or three HPV8-CER mice. Error bars 
represent the standard deviation. 
  
UVB-irradiation induced only small separated papillomas in HPV8-CER mice. For 
RNA analysis skin punch biopsies were taken out of papillomatous areas. Twelve 
days after UVB-irradiation both FVB/N wt and HPV8-CER mice showed an 
upregulated mK14 expression (Figure 9), which was similar to that observed for the 
combined UVA/B irradiation. In contrast, after UVA-irradiation mK14 expression was 
neither increased in FVB/N wt nor in HPV8-CER mice. This data demonstrates, that 
UVB radiation is responsible for the activation of the hK14-promoter and thus for the 
induction of the HPV8 oncogenes in transgenic mice. 
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4.1.7 Tape-stripping of HPV8-CER mouse skin induces papillomatosis 
and enhanced HPV8 oncogene expression 
 
Wounding of HPV8-CER mice by taking skin punch biopsies also induced papilloma 
development (Marcuzzi 2006). In this study the influence of mechanical skin irritation 
on transgene expression was investigated by tape-stripping the mouse skin. In 
contrast to the area-wide irritation by UVA/B-irradiation, tape-stripping only leads to 
small, light wounds and therefore represents a softer experimental approach to 
irritate the skin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Induction of papilloma growth in HPV8-CER mice by mechanical skin irritation. 
HPV8-CER mice were shaved and treated with depilatory cream on a 4 cm2 sized skin area and then 
treated by attaching and detaching 15 times a new piece of tape. Pictures show treated skin areas of 
one mouse at different points in time. 
 
Tape-stripping punctually led to wounds on small skin areas (Figure 10, 24h after 
treatment). These wounds macroscopically appeared to be healed up within ten 
days. However, starting from about day fourteen after treatment papilloma growth 
was visible particularly on skin areas, which had formerly been wounded more 
severely (Figure 10, 4d after treatment). These papillomas grew larger over the 
14d 
4d 10d 24h 
19d 29d 
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following observation period. As from day 19 after treatment, additional, small, spike-
shaped papillomas were detectable on the treated skin area. 
The influence of tape-stripping on transgene expression was investigated in three 
HPV8-CER mice two days after treatment. Four punch biopsies were taken from 
each mouse to measure HPV8-E6 expression in areas with different grades of injury 
(Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Severe mechanical skin irritation 
enhances HPV8-E6 expression early after treatment.  
Three HPV8-CER mice were shaved and treated with 
depilatory cream on a 4 cm2 sized skin area and then 
treated by attaching and detaching 15 times a new piece 
of tape. Two days after treatment four skin punch 
biopsies were taken from each mouse out of the treated 
skin area indicated by circles in the pictures. Additionally 
one skin punch biopsy was also taken from each mouse 
out of the untreated skin area. HPV8-E6 mRNA 
expression levels were measured in one microgram of 
reverse transcribed total cellular RNA by qRT-PCR. The 
HPV8-E6 level in irritated skin was normalized to the 
HPV8-E6 level in untreated skin of the same mouse. 
Bars represent the HPV8-E6 expression ratio of a single 
skin sample. 
 
 
 
Mouse A and B showed moderate to severe injuries and partially enhanced HPV8-E6 
expression, while mouse C had only minor wounds and normal HPV8-E6 expression 
(Figure 11). Overall, samples with a macroscopically visible lesion (A1, A2, A3, B1, 
B2) showed enhanced (1.5 - 2.9 fold) HPV8-E6 expression, while samples with no 
visible or only tiny lesions (A4, B3, B4, C1, C2, C3, C4) showed normal or slightly 
enhanced (0.8 - 1.5 fold) HPV8-E6 expression. 
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4.2 HPV8-E6 knock-down by specific siRNAs in cell culture and 
skin of HPV8-CER mice 
 
The similar phenotype of HPV8-E6 and HPV8-CER mice clearly demonstrates that 
E6 is the major oncogene in HPV8-CER mice (Marcuzzi 2006). In 4.1.2 and 4.1.7 it 
was shown that E6 expression is already enhanced one to two days after skin 
irritation in HPV8-CER mice, indicating that an early increase of E6 expression is of 
crucial importance for papilloma development. To substantiate this observation, 
experiments were designed to reduce or inhibit papilloma growth in HPV8-CER mice 
after irritation by topical application of HPV8-E6 specific siRNA. Prior to testing the 
designed siRNAs on the mouse skin, they had to be characterized in cell culture 
experiments regarding their ability to knock-down HPV8-E6. If successful this could 
also raise prospect for preventive treatment. 
 
4.2.1 Characterization of HPV8-E6 specific siRNAs in monolayer cell 
culture 
 
The silencing efficiency of a siRNA strongly depends on its target sequence. 
Therefore, four siRNAs with different target sites in HPV8-E6 were tested in cell 
culture to specify their silencing efficiency. All siRNAs (siRNA-HPV8E6-1, -2, -3, -4 
and siRNA-control-fluorescein) were designed and manufactured by Qiagen (Hilden). 
HaCaT-pLXSN8-E6 cells were transfected with “Lipofectamine 2000” and 50 nM 
(final concentration) siRNA-HPV8E6-1, -2, -3, -4, siRNA-control-fluorescein, 
respectively, as described in 3.2.4. The transfection reagent alone and the non-
silencing siRNA-control-fluorescein represent negative controls to rule out unspecific 
knock-down. RNA was isolated 24h after transfection and HPV8-E6 mRNA levels 
were measured by qRT-PCR. HPV8-E6 expression of control cells was comparable 
to that of untransfected HaCaT-pLXSN8-E6 cells, showing that there was no 
unspecific knockdown of HPV8-E6 expression (Figure 12). In contrast, HaCaT-
pLXSN8-E6 cells transfected with siRNA-HPV8E6-1 showed the highest knock-down 
leading to a remaining HPV8-E6 expression of 15%, followed by siRNA-HPV8E6-2 
with 17%, siRNA-HPV8E6-3 with 21% and siRNA-HPV8E6-4 with 25%. Therefore 
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siRNA-HPV8E6-1 and siRNA-HPV8E6-2 with the highest knock-down efficiencies 
were used in following cell culture experiments. 
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Figure 12: Silencing efficiency of four different siRNAs against HPV8-E6. 
HaCaT-pLXSN8-E6 cells (3 x 104) were transfected with “Lipofectamine 2000” and siRNA-HPV8E6-1, 
2, -3, -4 or siRNA-control-fluorescein, respectively, in a final concentration of 50 nM. RNA was isolated 
24h after transfection and reverse transcribed. HPV8-E6 levels were measured by qRT-PCR and 
normalized to β-actin (human). HPV8-E6 expression of untransfected HaCaT-pLXSN8-E6 cells was 
set to 100 %. Experiments were done in duplicate. 
 
Titration experiments were carried out with siRNA-HPV8E6-1, -2 and a combination 
of these two. Different concentrations of siRNAs were transfected in HaCaT-pLXSN8-
E6 cells. There was no noticeable difference in knock-down efficiency between 
siRNA-HPV8E6-1 and -2 for all concentrations (Figure 13). Furthermore, a 
combination of these two siRNAs did not increase the HPV8-E6 knock-down. The 
knock-down increased with rising siRNA concentrations to about 10% HPV8-E6 
expression with 50 nM siRNA, where E6 knock-down was at its maximum. A higher 
siRNA concentration (100 nM) did not further enhance the knock-down effect. From 
these results it is clearly seen that the knock-down efficiency depends on siRNA 
concentration. 
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Figure 13: Titration of siRNA-HPV8E6-1 and siRNA-HPV8E6-2. 
HaCaT-pLXSN8-E6 cells (3 x 104) were transfected with “Lipofectamine 2000” and siRNA-HPV8E6-1, 
-2 or a combination of these two siRNAs, respectively, in a final concentration of 3.125 nM; 6.25 nM; 
12.5 nM; 25 nM; 50 nM or 100 nM. RNA was isolated 24h after transfection and reverse transcribed. 
HPV8-E6 levels were measured by qPCR and normalized to β-actin (human). HPV8-E6 expression of 
untransfected HaCaT-pLXSN8-E6 cells was set to 100 %. Experiments were done in quadruplicate. 
 
As the maximal knock-down was observed with 50 nM siRNA, this concentration was 
used to characterize the knock-down kinetics at different points in time after 
transfection. As shown in figure 14, no significant difference in HPV8-E6 expression 
was found between siRNA-HPV8E6-1 or -2 transfected cells. Already 6h post 
transfection a clear HPV8-E6 knock-down of 55% was detected, which increased to a 
maximum knock-down of 90% at 24h and 30h post transfection. 48h after 
transfection the HPV8-E6 expression began to rise indicating the end of the efficient 
knock-down effect. 
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Figure 14: Duration of the siRNA induced HPV8-E6 knock-down in HaCaT-pLXSN8-E6 cells. 
HaCaT-pLXSN8-E6 cells (3 x 104) were transfected with “Lipofectamine 2000” and siRNA-HPV8E6-1 
or -2, respectively, in a final concentration of 50 nM. RNA was isolated 6h, 24h, 30h, 48h, 72h and 96h 
after transfection and reverse transcribed. HPV8-E6 levels were measured by qPCR and normalized 
to β-actin (human). HPV8-E6 expression of untransfected HaCaT-pLXSN8-E6 cells was set to 100 %. 
Experiments were done in duplicate. 
 
4.2.2 Topical application of a fluorescent siRNA on mouse skin 
 
In order to deliver the siRNA to the K14-expressing target cells in the mouse 
epidermis, different transfection reagents, pretreatment and penetration methods 
were evaluated with a fluorescein-linked siRNA. Initial transfection experiments with 
siRNA-control-fluorescein (10 µM) and the transfection reagents “In vivo-jetPEI”, 
“Lipofectamin 2000” or “MIKA-Nuclehicle-Kit”, applied on shaved and depilated 
HPV8-CER mouse skin, did not yield fluorescence signals in the epidermis above 
H2O treated mouse skin. Only trapped siRNA molecules in cornified cells and hair 
bulbs showed a distinct green fluorescence (Figure 15, left column). As an 
alternative, penetration of the skin by tattooing in cooperation with transfection 
reagents was tested to introduce siRNAs into the epidermal cells. The tattoo needles 
penetrate the dermis and epidermis, thereby delivering the siRNA to both layers and 
possibly allowing transfection of basal cells. SiRNA-control-fluorescein (10 µM) was 
used in combination with the different transfection reagents. These transfection-
mixes were tattooed into shaved and depilated HPV8-CER mice. Skin samples were 
taken 24h after application. 
 Figure 15: Tattoing is an effective method to introduce siRNAs into the epidermis
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Tattooing the mouse skin with “In vivo-jetPEI”/siRNA-control-fluorescein mix did not 
lead to a noticeable fluorescence above H2O-tattooed skin (Figure 15, right column). 
In contrast, siRNA-control-fluorescein tattooed with “Lipofectamin 2000” or “MIKA-
Nuclehicle-Kit” was visible in the epidermis and dermis. 
 
4.2.3 Knocking-down HPV8-E6 expression in HPV8-CER mice by 
tattooing gene specific siRNA 
 
The most promising method to deliver siRNA into mouse skin was tattooing in 
cooperation with “Lipofectamin 2000”. In initial tests it was demonstrated that simply 
tattooing HPV8-CER mouse skin induced papilloma development within two to three 
weeks, similar to tape-stripping. It was now tested, if this tattooing-induced 
papillomatosis could be reduced or even inhibited by tattooing HPV8-E6 specific 
siRNAs into HPV8-CER mouse skin. Ten HPV8-CER mice were tattooed with H2O 
and siRNA-HPV8E6-1(10 µM)/”Lipofectamin 2000”-mix on separate shaved and 
depilated skin areas at the same time as described in 3.6.2, thereby inducing 20 
wounds respectively. Images of tattooed skin were taken at different points in time. 
The wounds caused by tattooing H2O or siRNA/”Lipofectamin 2000” (Figure 16a) 
started to heal and the skin seemed to be restored around day ten after treatment. 
On day 18 after tattooing apparent differences between the two approaches were 
macroscopically visible. While there was only a small cicatricial spot in the siRNA-
HPV8E6-1 tattooed skin, papilloma development already started in the H2O treated 
area. Although on day 28 papilloma development was also visible on some wounds 
of the siRNA-HPV8E6-1 tattooed area it was remarkably slowed down and reduced. 
On day 42 a few siRNA-HPV8E6-1 tattooed areas still showed no papillomatosis and 
the emerged papillomas remained small and locally restricted to the wound areas in 
contrast to the pronounced papillomas in the H2O treated areas, which overgrew the 
wound areas. The Kaplan-Meier curves in figure 16b show a delay of ten days in 
papilloma development between wounds induced by tattooing siRNA-HPV8E6-1 and 
H2O into HPV8-CER mouse skin. The most prominent observation was that 
papillomatosis was detected in 15 out of 20 wounds (75%) induced by tattooing H2O, 
while only 9 out of 20 wounds (45%) induced by tattooing siRNA-HPV8E6-1 
developed papillomas. 
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Figure 16: Tattoing HPV8-E6 specific siRNA slowed down papillomatosis in HPV8-CER mice. 
Ten HPV8-CER mice were shaved and depilated. Afterwards 20 µl H2O and 20 µl of the transfection-
mix siRNA-HPV8E6-1(10 µM)/Lipofectamin 2000 was tattooed into separate areas of the mouse skin 
as described in 3.6.2. (a) Images show tattooed skin areas of four mice one day and 42 days after 
tattooing. H2O was tattooed cranial siRNA-HPV8E6-1 caudal. (b) Kaplan-Meier curves showing the 
percentage of papilloma development of 20 H2O- and 20 siRNA-tattoed HPV8-CER skin areas plotted 
against time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p < 0,005 
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4.3 Cellular miRNA expression in HPV8 expressing cells 
 
4.3.1 MiRNA expression levels in healthy skin of FVB/N wt and HPV8-
CER mice 
 
As described in 1.8.3 miRNAs are important regulators of cellular gene expression. 
Their deregulated expression has recently been associated with several types of 
cancer (Croce and Calin 2005), but also with viral infections for example HPV16 and 
hepatitis C virus (Wang et al. 2008; Braconi et al. 2010). To get a first insight into a 
possibly deregulated miRNA population mediated by HPV8, a comparative miRNA 
microarray (LC Sciences, Houston, USA) was performed with total RNA from non-
lesional skin of HPV8-CER and FVB/N wt mice. 
 
miRNA FVB/N wt signal HPV8-CER signal ratio 
mmu-miR-7 1 140,2 140,2 
mmu-miR-17-5p 368,6 754,4 2,05 
mmu-miR-20b 88,2 300,2 3,4 
mmu-miR-21 7672,2 17313,4 2,26 
mmu-miR-31 252,7 573,1 2,27 
mmu-miR-106a 6,5 94,3 14,51 
mmu-miR-133a* 131,7 17,4 0,13 
mmu-miR-133a 1737,3 454,3 0,26 
mmu-miR-133b 1599,6 444,9 0,28 
mmu-miR-141 197,8 54 0,27 
mmu-miR-145 3767,7 1351 0,36 
mmu-miR-146b 480,1 1221,9 2,55 
mmu-miR-150 473,7 194 0,41 
mmu-miR-155 73,7 381 5,17 
mmu-miR-181b 271 750,2 2,77 
mmu-miR-200a 6898 1716,5 0,25 
mmu-miR-206 25941,3 8176,4 0,32 
mmu-miR-207 41,1 209 5,09 
mmu-miR-218 19,3 165,5 8,58 
mmu-miR-222 708,7 289,8 0,41 
mmu-miR-224 36 121,3 3,37 
mmu-miR-290 16,4 78,2 4,77 
mmu-miR-346 154,7 611,9 3,96 
mmu-miR-374-5p 11,1 116,3 10,48 
mmu-miR-422b 726,2 294,3 0,41 
mmu-miR-467a 100,1 365,6 3,65 
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mmu-miR-467b 165,4 841,8 5,09 
mmu-miR-468 16,1 112,8 7,01 
mmu-miR-652 205,1 72,3 0,35 
mmu-miR-671 183,7 348,4 1,90 
mmu-miR-674-5p 145 374 2,58 
mmu-miR-680 45,3 276,1 6,09 
mmu-miR-689 695,3 1974,5 2,84 
mmu-miR-705 1503,4 3784,2 2,52 
mmu-miR-721 1 70,9 70,90 
 
Table 2: 35 miRNAs were found to be more than two-fold deregulated in their expression in 
healthy skin of HPV8-CER mice compared to FVB/N wt mice.  
Five microgram total RNA from healthy skin of one FVB/N wt and one HPV8-CER mouse were used to 
perform a comparative miRNA microarray (LC Sciences, Houston, USA). Signal intensity was 
measured in triplicate. Table shows mean intensity and HPV8-CER:FVB/N wt ratio. 
 
Out of 358 tested miRNAs, 129 were found to be expressed in the FVB/N wt skin and 
249 in the skin of HPV8-CER mice (data not shown). However, many of the detected 
miRNAs in HPV8-CER mouse skin were only slightly above the background noise 
and were therefore not considered. 35 miRNAs (Table 2) were found to be more than 
two-fold deregulated in their expression in the skin of HPV8-CER mice compared to 
FVB/N wt skin (24 upregulated and 11 downregulated). Many of these miRNAs 
showed low signal intensities indicating low level of these miRNAs in untreated skin, 
which makes it difficult to perform an exact measurement and subsequent evaluation. 
Based on this primary search the transcription kinetics of 30 miRNAs were 
determined in FVB/N wt and HPV8-CER mice after UV-irradiation, to check if the 
expression of certain miRNAs becomes altered during UVA/B-induced papilloma 
development and if this expression correlates with the rising HPV8 transgene 
expression. These 30 miRNAs were selected either because of their known 
involvement in carcinogenic processes or their prominent deregulation in HPV8-CER 
mice compared to FVB/N wt mice according to the microarray data. 
In HPV8-CER mice miRNA-17-5p (Figure 17a) and miRNA-20b (Figure 17b) showed 
a moderately higher expression level than in FVB/N wt mice both in untreated skin 
and 6h, 1d and 2d after irradiation. In both mouse strains the total expression 
dropped six hours after UVA/B but rose again until day two after UVA/B-irradiation, in 
the case of HPV8-CER mice higher than in untreated skin. The remaining points in 
time were quite similar in FVB/N wt and HPV8-CER mice, except for day 30, where 
expression was again enhanced in HPV8-CER mice. In both mouse strains the 
expression of miRNA-21 (Figure 17c) rose until day 12 after UVA/B-irradiation. 
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However, starting on day 18 the expression returned to a basal level in FVB/N wt 
mice, whereas it persisted at an upregulated level in HPV8-CER mice. MiRNA-106a 
(Figure 17d) showed a similar expression profile like miRNA-20b, which are both 
members of the same miRNA cluster. But the difference between the enhanced 
expression in HPV8-CER mice compared to the unaltered or reduced expression in 
FVB/N wt mice on day 18, 24 and 30 after UVA/B-irradiation was more distinct for 
miRNA-106a. For miRNA-155 (Figure 17e) the expression was already lower in 
untreated HPV8-CER mouse skin compared to FVB/N wt mouse skin. This reduction 
of expression was maintained at all observed points in time after UVA/B-irradiation. 
The expression of miRNA-206 (Figure 17f) started to drop two days after UVA/B-
irradiation in both mouse strains and was further decreased on day 18, 24 and 30. 
However, at all points in time after day seven miRNA-206 was lower in HPV8-CER 
mice than in FVB/N wt mice. A more drastic effect was observed for miRNA-374-5p 
(Figure 17g). Until day one after UVA/B-irradiation the expression was higher in 
HPV8-CER than in FVB/N wt mice. Starting from day two the expression decreased 
in HPV8-CER mice, significantly on day 30, while it stayed at basal level in FVB/N wt 
mice. Except for the untreated skin, the expression of miRNA-689 (Figure 17h) was 
at all points in time in HPV8-CER mice lower than in FVB/N wt mice, especially at 
late points in time. 
These results demonstrate that the enhanced HPV8 oncogene expression after 
UVA/B-irradiation is paralleled by an expression deregulation of certain miRNAs. 
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Figure 17a-h: Expression kinetics of deregulated miRNAs in UVA/B-irradiated HPV8-CER and FVB/N wt mice. 
Back skin areas (4 cm2) of shaved HPV8-CER and FVB/N wt mice were irradiated with 10 J/cm2 UVA and 1 J/cm2 UVB. Skin punch biopsies of three to six 
mice were taken at different points in time after UVA/B-irradiation out of the irradiated skin. Additionally skin biopsies from untreated skin of these mice were 
taken. MiRNA expression levels were measured in one microgram of reverse transcribed total cellular RNA by qRT-PCR and normalized to miRNA-127. The 
results were further normalized to the median expression of the respective miRNA in untreated FVB/N wt skin. The mean expression ratio of different miRNAs 
is plotted against time. Error bars represent standard deviation. 
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There was no difference in miRNA-21 expression pattern in untreated skin of HPV8-
CER and FVB/N wt mice. Both mouse lines showed a panepithelial staining and 
signals in the dermal compartment (Figure 18a). On day 2 and 24 after UVA/B-
irradiation the expression was enhanced in HPV8-CER mice compared to FVB/N wt 
animals. MiRNA-106a showed overall a more cytoplasmatic expression (Figure 18b). 
Similar to miRNA-21, miRNA-106a showed no difference between the expression 
pattern of non-lesional HPV8-CER and FVB/N wt mouse skin. While the expression 
was weaker in FVB/N wt mice 2 and 24 days after UVA/B-irradiation it was generally 
enhanced in HPV8-CER mice but gradually decreased in the uppermost 
differentiated cell layers. MiRNA-155 showed an overall low expression. In untreated 
skin of HPV8-CER mice miRNA-155 expression was slightly lower than in untreated 
skin of FVB/N wt mice (Figure 18c). Two days after UVA/B-irradiation it was 
enhanced in FVB/N wt mice, while it was reduced in HPV8-CER mice, particularly in 
the suprabasal cells of the epidermis. Twenty-four days after irradiation miRNA-155 
signals were reduced in epidermal cells and almost exclusively nuclear in HPV8-CER 
mice compared to FVB/N wt mice, where also cytoplasmatic signals were visible. A 
slight reduction was also observed in dermal cells of HPV8-CER mice compared to 
FVB/N wt mice. The expression of miRNA-206 was equivalent in untreated skin of 
both mouse strains (Figure 18d). There was an increase of miRNA-206 expression 
detectable two days after UVA/B-irradiation in FVB/N wt mice, which decreased 24 
days after UVA/B-irradiation, but was still higher than in HPV8-CER mice, with 
predominantly cytoplasmatic localization. In contrast, in HPV8-CER mice a 
decreased and primarily nuclear miRNA-206 expression was found on day two and 
24 after UVA/B-irradiation. 
Overall, the ISH data confirm the qRT-PCR results and therefore further confirms the 
notion of deregulated miRNAs in HPV8 oncogene expressing cells. 
 
4.3.3 Expression alterations of cellular targets of deregulated miRNAs in 
HPV8-CER mice 
 
To test, whether deregulated miRNAs observed in HPV8-CER mice by qRT-PCR and 
ISH actually affected the expression of their respective cellular targets IHC stainings 
were performed. MiRNA-17-5p and miRNA-21 are both able to downregulate the 
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phosphatase and tensin homolog (PTEN) (Lewis et al. 2003; Meng et al. 2007). 
Since these two miRNAs were upregulated in HPV8-CER mice after UVA/B-
irradiation in contrast to FVB/N wt animals (Figure 17a, c) the protein level of PTEN 
was expected to be downregulated in HPV8-CER mice. There was no difference in 
the PTEN protein level between untreated FVB/N wt and HPV8-CER mouse skin. 
Both showed distinct signals in the epidermis and hair follicles (Figure 19a). Two 
days after UVA/B-irradiation the PTEN level was enhanced in FVB/N wt mice 
whereas it was reduced in HPV8-CER mouse skin. This expression pattern was 
preserved 24 days after UVA/B-irradiation in both mouse lines. PTEN was detected 
in the cytoplasm at all points in time in both mouse strains. Another target of miRNA-
21 is the tumor suppressor programmed cell death 4 (PDCD4) (Frankel et al. 2008), 
which was found in the nucleus and in the cytoplasm in epidermal cells of untreated 
skin of FVB/N wt and HPV8-CER mice (Figure 19b). Two days after UVA/B-
irradiation the staining was more nuclear in HPV8-CER mice compared to FVB/N wt 
mice. Remarkably, 24 days after irradiation, PDCD4 was exclusively nuclear and 
reduced in HPV8-CER mice, while it returned to its basal level with nuclear and 
cytoplasmatic localization in FVB/N wt mice. For the tumor suppressor Rb, a known 
cellular target for miRNA-106a (Volinia et al. 2006), a pronounced expression was 
detected in the cytoplasm and the nucleus of untreated skin of FVB/N wt and HPV8-
CER mice (Figure 19c). Two and twenty-four days after UVA/B-irradiation, where 
miRNA106a expression is upregulated in HPV8-CER mice (Figure 17d), Rb 
expression is reduced, especially in the lower epidermal cell layers of these mice. At 
the same points in time staining was intensive in FVB/N wt mice. It was shown that 
miRNA-155 downregulates the expression of the keratinocyte growth factor (KGF), a 
member of the fibroblast growth factor family (Pottier et al. 2009). Therefore the KGF 
expression was expected to be upregulated in HPV8-CER mice since miRNA-155 
levels were reduced (Figure 17e). KGF expression in HPV8-CER rose after UVA/B-
irradiation in a differentiation-dependant manner showing a higher expression in the 
uppermost differentiated cells. In FVB/N wt mice the KGF expression was not 
changed after UVA/B-irradiation (Figure 19d). In both mouse strains KGF was 
detected exclusively in the cytoplasm for all points in time. Recently, it could be 
shown that miRNA-206 downregulates the proto-oncogene mesenchymal-epithelial 
transition factor (MET) also known as hepatocyte growth factor receptor (Yan et al. 
2009). The decrease of miRNA-206 in HPV8-CER mice starting two days after 
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Figure 19: Confirmation of expression alteration of cellular 
FVB/N wt mice after UVA/B-irradiation.
Dorsal skin areas (4 cm2) of shaved HPV8
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4.3.4 HPV8-E6 mice show similar miRNA expression deregulations after 
UVA/B-irradiation as HPV8-CER mice 
 
To compare the UVA/B-induced miRNA expression alterations of HPV8-CER mice 
with the miRNA expression of HPV8-E6 mice, known to have a similar tumor 
phenotype, punch biopsies were taken out of the irradiated and non-irradiated skin of 
HPV8-E6 animals 7 and 24 days after treatment. 
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Figure 20: HPV8-E6 mice showed similar miRNA expression deregulations as HPV8-CER mice. 
Back skin areas (4 cm2) of shaved HPV8-E6 mice were irradiated with 10 J/cm2 UVA and 1 J/cm2 
UVB. Skin punch biopsies were taken 7 and 24 days after UVA/B-irradiation from four mice each, out 
of the irradiated and non-irradiated skin. MiRNA expression levels were measured in one microgram of 
reverse transcribed total cellular RNA by qRT-PCR and normalized to miRNA-127. The results were 
further normalized to the median expression of the respective miRNA in untreated FVB/N wt skin. The 
mean expression ratio of different miRNAs is plotted against time. Error bars represent standard 
deviation. 
 
In untreated skin of HPV8-E6 mice the expression of miRNA-17-5p (Figure 20) was 
lower than in FVB/N wt or HPV8-CER mice. On day seven after UVA/B-irradiation 
expression started to increase and was further enhanced on day 24 after UVA/B-
irradiation similar to HPV8-CER mice. Expressions of miRNA-20b and -106a were 
reduced in untreated skin of HPV8-E6 mice compared to HPV8-CER or FVB/N wt 
mice, but they were enhanced on day 7 and 24 after UVA/B-irradiation just like in 
HPV8-CER mice. A similar miRNA-21 expression profile was measured in untreated 
and UVA/B-irradiated skin of HPV8-E6 and -CER mice. 
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4.3.5 The tendency of miRNA alterations in HPV8 transgenic mice is 
mirrored in HPV8-CER expressing human keratinocytes 
 
To verify the miRNA expression alterations observed in HPV8 transgenic mice in a 
human system, monolayer cell culture experiments were performed with the human 
keratinocyte line PM1. These cells were retrovirally infected with viruses coding for 
the empty retroviral vector pLXSN or for the complete early region of HPV8 pLXSN-8-
CER. Total RNA was isolated from drug selected stable cells and miRNA expression 
levels were measured by qRT-PCR. 
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Figure 21: The miRNA expression alterations measured in UV-irradiated HPV8-CER mice were 
also observed in the human keratinocyte cell line PM1-pLXSN8-CER. 
Total RNA was isolated from PM1-pLXSN cells and PM1-pLXSN8-CER cells. MiRNA expression 
levels were measured in one microgram of reverse transcribed total cellular RNA by qRT-PCR and 
normalized to miRNA-127. The results were further normalized to the expression of the respective 
miRNA in control cells. Bars represent mean miRNA expression ratios between PM1-pLXSN8-CER 
cells and PM1-pLXSN cells. Error bars represent standard deviation.  
 
MiRNA-17-5p, -20b, -21 and -106a were upregulated in PM1-pLXSN8-CER cells 
compared to the control cells, in contrast to miRNA-206 and -374-5p which were 
unaffected or downregulated (Figure 21). These results are partially consistent with 
the miRNA data obtained from untreated skin of HPV8-CER mice and highly 
conformable with the miRNA data obtained from UVA/B-irradiated HPV8-CER mice. 
Although the alterations of miRNA expression were minor in cell culture, they showed 
the same tendency, supporting an HPV8-dependent deregulation of miRNA 
expression in humans. 
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5 Discussion 
 
The oncogenic potential of HPV8 in the skin of transgenic mouse lines was recently 
shown (Schaper et al. 2005; Marcuzzi 2006; Pfefferle et al. 2008). UV-irradiation and 
mechanical wounding leads to a synchronized papilloma development in these mice 
within three weeks. However, little is known about the triggers of tumorous skin 
growth. To clarify the role of skin wounding and its influence on HPV expression in 
the early stages of tumor development in the HPV8 transgenics, the kinetics and 
levels of transgene expression were analyzed in response to exogenous skin 
irritations induced by UVA/B-irradiation or mechanical wounding. 
In prevenient experiments the expression levels of the oncogenes HPV8-E2, -E6 and 
-E7 were found to be equally expressed from the hK14-promoter. Therefore it can be 
presumed that a deregulation of one of these genes implicates the same 
deregulation of the other genes. These results are in contrast to a previous study, 
where it was reported that the E2 transcript level was at least ten times higher than 
the E6 and E7 levels (Schaper et al. 2005). This discrepancy, however, can be 
explained by the use of different primers for reverse transcription (Stahlberg et al. 
2004). Whereas Schaper et al. (2005) used oligo-dT23-primers, a mixture of oligo-
dT23-primers and random nonamers was used in the present study. The long HPV8 
transcript, in particular the 5’ proximal genes E6 and E7, was obviously more 
efficiently reverse transcribed by this primer combination. Hence the combination of 
oligo-dT23-primers and random nonamers was used to measure kinetics of transgene 
expression in the skin of HPV8 transgenic mice irritated by tape-stripping or UV. 
It is known that UV-irradiation, the main risk factor for SCC development (Leiter and 
Garbe 2008), can induce the cellular K14-promoter (Kinouchi et al. 2002) as well as 
the viral oncogene promoter of HPV5 and 8 (Akgül et al. 2005). Therefore, mK14 and 
HPV8-E6 levels were determined in transgenic and FVB/N wt skin during UV-induced 
papillomatosis. Irradiation induced enhanced mK14 expression levels in both strains, 
reaching maximum levels two to four days after induction. However, whereas the 
level of mK14 mRNA gradually returned to normal starting around day twelve in the 
FVB/N wt mice, the high level of mK14 mRNA persisted in the transgenics. 
Analogously to the mK14, the HPV8-E6 expression and thus the HPV8-E2 and -E7 
expression were also constantly enhanced starting from day one after skin irritation. 
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In parallel, hyperplasia induced by UVA/B-irradiation resolved within three weeks in 
FVB/N wt mice, while the enhanced transgene expression led to papilloma 
development in HPV8-CER mice. Perpetuation of epidermal growth and enhanced 
transgene expression were also seen for UVA/B-irradiated mice of the HPV8-E6 
strain and underline the necessity of elevated transgene expression for papilloma 
development. IHC staining for HPV8-E2 protein in sections from UVA/B-irradiated 
HPV8-CER skin confirmed increased transgene expression already one day after 
induction. These data suggest that increased HPV8 oncogene expression is crucial 
in the early steps of papilloma development. The observation that almost all 
keratinocytes which emerged during papillomatosis were positive for HPV8-E2 
protein (E2 is only expressed in cells with an active K14-promoter) together with the 
finding of enhanced mK14 levels (K14, a marker for basal cells) in irradiated HPV8-
CER mice may indicate a gain of a basal cell phenotype. It is tempting to speculate 
that HPV8 is able either to maintain proliferative signals or to circumvent cell 
differentiation to preserve the basal phenotype. It is also noteworthy that HPV8-E2 
was predominantly localized in the cytoplasm until day ten after UVA/B-irradiation, 
when it was additionally detectable in the nucleus. Since HPV8-E2 is a transcription 
factor, it is reasonable to find it in the nucleus. E2 can regulate HPV8 as well as 
cellular gene expression. For example, E2 downregulates the cellular gene β4-
integrin, which leads to the egress of keratinocytes from the basal to suprabasal 
layers (Oldak et al. 2004). 
In the HPV8-CER mice, UVB-irradiation alone induced only small separated 
papillomas, whereas UVA plus UVB induced confluent papilloma development in the 
irradiated skin area. However, the HPV8 transgene levels in papillomatous areas 
elicited by either UVB or UVA/UVB irradiation were similar. UVA-irradiation alone 
enhanced neither mK14 expression nor papilloma development. Thus, UVB is the 
decisive cause of UVA/B-induced enhanced transgene expression and tumor growth, 
but synergistic effects of UVA apparently further promote UVB-induced papilloma 
development (Marcuzzi 2006), possibly by causing oxidative stress (Burke and Wei 
2009). 
Papillomas also developed spontaneously in non-irradiated HPV8-CER mice, but at 
slower rates. Without UVA/B-irradiation, spontaneous tumors arose mostly dorsal 
caudal and more frequently in male HPV8-CER mice, despite a constitutive, low level 
transgene expression in the entire mouse epidermis (Schaper et al. 2005; Marcuzzi 
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2006; Pfefferle et al. 2008). Since male mice fight more than female mice, it was 
speculated that fight wounds might enhance tumor development. Several reports 
showed enhanced K14 expression in hyperplastic skin (Coussens et al. 1996; 
Rossiter et al. 2001; Sethi and Palefsky 2004). Hence, the question came up, if skin 
regeneration processes in general might be sufficient to induce papillomas in HPV8-
CER mice. To test this, mice were wounded by tape-stripping and papilloma 
development was indeed observed. In contrast to the area wide papillomatous 
growth elicited by UVA/B-irradiation, tape-stripping elicited only small discrete 
papillomas. The HPV8-E6 expression levels observed in tape-stripped skin areas of 
HPV8-CER mice were overall less pronounced than those observed in UVA/B-
irradiated areas. This may point to only few stimulated keratinocytes in tape-stripped 
skin in contrast to UVA/B-irradiated areas for which the stimulation of the majority of 
keratinocytes may be expected with the associated enhanced risk for tumor growth. 
In line with this, the severity of skin wounding by tape-stripping appeared to correlate 
with enhanced transgene expression two days after treatment and with the 
probability of papilloma induction. A similar situation could be supposed for UVB-
irradiated mice, where enhanced mK14 levels were found in papillomatous skin 
areas and presumably low levels in non-lesional but also UVB-irradiated skin areas. 
However, this has not yet been confirmed experimentally. Since wounds from tape-
stripping are comparable to wounds from scratching or fighting, it is conceivable that 
many of the spontaneous papillomas actually arose from wounds. This concept is 
further supported by previous reports, in which enhanced amounts of viral DNA and 
subsequent papilloma development was observed after activation of latent mastomys 
natalensis papillomavirus and cottontail rabbit papillomavirus (CRPV) infections by 
mild mechanical skin irritation (Siegsmund et al. 1991; Amella et al. 1994). In a later 
report, it was shown that CRPV could also be activated by UVA/B-irradiation (Zhang 
et al. 1999). Regarding enhanced expression levels, the conversion of a latent beta-
HPV infection into an activated infection can be mirrored by the hK14-HPV8 
transgenic animals. With this model it was demonstrated that enhanced expression 
levels of HPV8 lead to a perpetuation of tumorous processes in the course of skin 
regeneration processes and may be a key step in early skin carcinogenesis. 
To substantiate this assumption HPV8-E6-specific siRNAs were topically applied on 
HPV8-CER mouse skin to knock down E6 expression at early points in time. The 
delivery of the siRNA to its target cells, the basal cells, was checked with a 
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fluorescent control siRNA. To overcome the densely packed corneocytes an invasive 
delivery with a high siRNA concentration is recommended  (Geusens et al. 2009). 
Accordingly, the attempt to introduce the fluorescent siRNA into the skin of HPV8-
CER mice using only transfection reagents did not work, whereas in combination with 
a tattoo machine definite fluorescence was observed in the epidermis. Therefore the 
tattoo approach was used for the knock-down experiment in HPV8-CER mice. In the 
H2O-tattooed skin area papillomas developed in 75% of the cases and were 
macroscopically visible approximately on day 18 after tattooing. A significant 
difference was achieved by tattooing E6 specific siRNA, where papilloma 
development was reduced or even inhibited. In these areas papillomas developed 
only in 45%, which were not macroscopically visible until approximately day 28 after 
tattooing. In these animals papilloma development may be due to an inconsistent 
delivery of the siRNA. This would support the assumption that only few HPV8-E6 
positive cells are necessary to induce papillomatosis. As shown in cell culture 
experiments the efficient HPV8-E6 knock-down lasts about four days after 
transfection, with a maximal level around 30h after siRNA transfection. Similar 
observations were reported for siRNAs injected into mice, where the knock-down 
decreased after reaching its maximal level on day one or two after injection (Layzer 
et al. 2004; Nishina et al. 2008). When assuming that the knock-down also lasts only 
few days in the skin of HPV8-CER mice, the knock-down of induced HPV8-E6 
expression seems to have a great impact on papilloma development in HPV8-CER 
mice. This would be a strong indication that HPV8 gene expression is crucial in the 
early steps of papillomatosis in mice and most probably also in immunosuppressed 
and epidermodysplasia verruciformis patients. 
The reduced penetrance of tumor development after the less efficient induction of 
transgene expression following abrasive skin irritations compared to UVA/B-
irradiation furthermore points to a dose-response relationship between oncogene 
expression and tumor development. This notion is supported by the finding that the 
level of HPV8-E2 mRNA in different HPV8-E2 transgenic mouse lines has an 
influence on the prevalence and rate of tumor development in these mice (Pfefferle et 
al. 2008). These data together with the observation that only HPV8-E2 mice with a 
high E2 expression level after UVA/B-irradiation developed tumors indicate the 
necessity of a certain threshold of oncogene expression for transformation of 
keratinocytes. Interestingly, also for EV patients, who are at a strongly increased risk 
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for SCC development, high beta-HPV DNA levels could be shown (Dell'Oste et al. 
2009). Thus, within the first steps of HPV associated skin carcinogenesis enhanced 
beta-HPV oncogene levels, caused either by promoter induction in the mouse model 
or in humans by immunosuppression or genetic defects, seems to elevate the risk for 
tumor development. 
Kinetics of selected cellular miRNAs and their respective targets were determined in 
HPV8-CER and FVB/N wt mice after UVA/B-irradiation to detect a possible 
deregulation, as it has been reported for several types of cancer (Croce and Calin 
2005), but also for viral infections for example HPV16 and hepatitis C virus (Wang et 
al. 2008; Braconi et al. 2010). The miRNA kinetics obtained from irradiated HPV8-
CER mice were checked for a correlation with the enhanced transgene expression. It 
was noted that there were differences between microarray and qRT-PCR results for 
some miRNAs in untreated skin of FVB/N wt and HPV8-CER mice. Differences 
between microarray and qRT-PCR data have often been described (Canales et al. 
2006; Chen et al. 2009; Zhang et al. 2009; Buchtova et al. 2010). Microarrays have a 
lower sensitivity than qRT-PCRs, which makes an exact measurement of low miRNA 
quantities by microarray impossible. Therefore, it is necessary to confirm or confute 
the microarray data by qRT-PCR, which is accepted to be the most appropriate 
method for this purpose because of its high sensitivity and accuracy (Provenzano 
and Mocellin 2007; VanGuilder et al. 2008; Li and Ruan 2009). The array detected 
just marginal levels for miRNA-106a and -374-5p in untreated skin of FVB/N wt mice 
compared to HPV8-CER mice, whereas ISH and qRT-PCR results clearly showed 
that there is no difference between untreated skin of FVB/N wt and HPV8-CER mice. 
The miRNA-155 results obtained from the array are also precarious, because both, 
qRT-PCR and ISH showed a downregulation of miRNA-155 expression in untreated 
skin of HPV8-CER mice, which is in contrast to the array. In the microarray, a lower 
level of miRNA-206 was measured in untreated skin of HPV8-CER mice compared to 
FVB/N wt mice, but this reduction was not measured until day two after irradiation in 
qRT-PCR and ISH. This discrepancy may be due to the fact that the HPV8-CER skin 
used in the microarray already exhibited inconspicuous skin alterations, leading to a 
reduced miRNA-206 expression. Moreover, the array was performed with only one 
FVB/N wt and one HPV8-CER mouse, while the qRT-PCR experiments with 
untreated skin were done with at least six mice, respectively. These findings endorse 
the accuracy of the qRT-PCR results. 
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MiRNA-15a, -16 and -34a are commonly deregulated in cancer tissue (Cimmino et al. 
2005; Iorio et al. 2005), but they were not altered in irradiated HPV8-CER mice (data 
not shown). 
MiRNA-17-5p is a member of the miRNA-17-92 cluster on chromosome 13q31 along 
with miRNA-18a, -19a, -19b-1, -20a and -92a-1. These miRNAs promote proliferation 
and inhibit apoptosis and are commonly overexpressed in lymphoma, colon, lung, 
breast and pancreas cancer (Hayashita et al. 2005; He et al. 2005; Volinia et al. 
2006; Mendell 2008). Important for the anti-apoptotic effects of the miRNA-17-92 
cluster is the down-modulation of the tumor suppressor PTEN (reviewed in Garzon et 
al. 2009). PTEN negatively regulates phosphatidylinositol-3,4,5-trisphosphate (PIP3) 
levels and the AKT signaling pathway (Jiang and Liu 2009). Therefore, the 
upregulation of miRNA-17-5p in HPV8-CER mice at early points in time after UV-
irradiation may favor papilloma development by downregulation of PTEN (Figure 22), 
which was verified by IHC two and twenty-four days after UVA/B-irradiation. 
Confirmed by microarray other miRNAs from the miRNA-17-92 cluster were also 
upregulated in untreated skin of HPV8-CER mice compared to FVB/N mice although 
not as strong as miRNA-17-5p (data not shown). 
The oncogenic miRNA-21 was found to be upregulated in a wide variety of 
hematological and solid cancers (Chan et al. 2005; Volinia et al. 2006) and 
overexpression of this miRNA in the breast cancer cell line MCF-7 promoted soft 
agar colony formation (Lu et al. 2008). MiRNA-21 inhibits the translation of the tumor 
suppressor genes PTEN (Meng et al. 2007) and PDCD4 (Frankel et al. 2008). The 
enhanced miRNA-21 expression in irradiated HPV8-CER mice, proven by qRT-PCR 
and ISH, should therefore lead to reduced PTEN and PDCD4 levels. The moderate 
downregulation of PTEN was already described above and is possibly a result of a 
combined effect of overexpressed miRNA-17-5p and miRNA-21 (Figure 22). 
Moreover cytoplasmatic PDCD4 protein level was strongly reduced in HPV8-CER 
mice 24 days after UV-irradiation as confirmed by IHC. PDCD4 inhibits tumor-
promoter induced neoplastic transformation, cell cycle progression and proliferation 
by regulating multiple proteins at the transcriptional and translational level. For 
example PDCD4 induces p21, inhibits AKT and interferes with the mitogen-activated 
protein kinase (MAPK) pathway resulting in activator protein 1 (AP-1) inhibition 
(Lankat-Buttgereit and Goke 2009). Targeting cytoplasmic PDCD4 therefore may 
support tumorigenic processes (Figure 22). 
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Volinia et al. (2006) found a strong functional interaction between the Rb 3′UTR and 
miRNA-106a. This finding suggests a posttranscriptional mechanism for regulation of 
Rb. Rb was found to be downregulated in gastric, prostate and lung tumor samples 
and miRNA-106a was overexpressed. Thus, the immunohistochemically confirmed 
Rb reduction in HPV8-CER mouse skin two and twenty-four days after UV-irradiation 
could be caused by the upregulated miRNA-106a expression at these points in time. 
This is supported by the finding that miRNA-106a and Rb showed an inverse 
complementary expression pattern in ISH and IHC stainings. The minor expression of 
Rb in the lower epidermal cell layers correlated with the higher expression of miRNA-
106a in these cells. Rb prevents the cell from progression through the cell cycle 
when it is bound to a transcription factor of the E2F-family. The loss of Rb in HPV8-
CER mice and with it a controlled cell cycle, drives the cell into excessive growth 
(Figure 22). The fact that Rb is also downregulated in primary human adult 
keratinocytes expressing all HPV8 early genes is supporting the HPV8-mediated Rb 
downregulation (Akgül et al. 2007). The upregulation of miRNA-20b in irradiated 
HPV8-CER mice is substantiating the overexpression measured for miRNA-106a, 
because these miRNAs are both members of the same miRNA cluster. 
MiRNA-155 knockout mice are immunodeficient, have defective B- and T-lymphocyte 
and dendritic cell functions, and show abnormal cytokine and chemokine expression 
(Rodriguez et al. 2007). Another group could show that Th cell differentiation in 
BIC/miRNA-155-/- mice is shifted towards Th2 cells (Thai et al. 2007). Therefore, the 
reduced miRNA-155 expression level in HPV8-CER mice at all observed points in 
time compared to FVB/N wt mice may indicate that HPV8 has a possible negative 
influence on the mouse immune system. When transferring these findings to humans 
it is tempting to speculate that beside the known immunosuppressive effects of UV-
light on the skin additional HPV8-mediated immunosuppressive effects through 
downregulation of miRNA-155 expression may synergistically contribute to a local 
immunosuppression, which can promote papillomatosis. Furthermore, miRNA-155 
also inhibits the translation of KGF and consequently a downregulation of miRNA-
155 leads to an increase of KGF protein (Pottier et al. 2009). Several studies 
reported enhanced KGF expression in different cancer specimen, which is 
accompanied by proliferative, invasive and cell survival effects. KGF is produced in 
cells of mesenchymal origin through stimulation of interleukin 1-α (IL1-α) secreted 
from keratinocytes and acts exclusively through the KGF receptor, which is 
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expressed primarily by epithelial cells (Figure 22). KGF has diverse roles, for 
instance regulating cell proliferation, migration, differentiation during vertebrate 
development, as well as tissue repair (Finch and Rubin 2006). Interestingly 
transgenic mice expressing KGF under the hK14-promoter showed hyperthickening 
and alterations of the differentiation pattern of epidermal tissue (Guo et al. 1993). 
Furthermore, engineered skin equivalents with KGF-expressing human keratinocytes 
showed increased proliferation of basal cells and keratinocytes residing in the 
normally quiescent suprabasal layers of the epidermis (Andreadis et al. 2001). 
Similar hyperproliferative activities were observed in UV-irradiated HPV8-CER mice 
where enhanced KGF protein levels were observed by IHC, may be caused by the 
reduced miRNA-155 level in mesenchmal cells. This downregulation of miRNA-155 is 
possibly accomplished by an enhanced transforming growth factor-β (TGF-β) 
secretion, which is known to downregulate miRNA-155 (Pottier et al. 2009). Indeed, 
upregulation of TGF-β expression has been reported for UV-irradiated keratinocytes 
immortalized with HPV38 (Dell'oste et al. 2008). 
In a recent study, it was shown that miRNA-206 downregulates the proto-oncogene 
MET (Yan et al. 2009). In contrast, this factor is upregulated in a variety of tumors 
including oral squamous cell cancer, but also after skin injuries (Di Renzo et al. 1994; 
Ferracini et al. 1995; Natali et al. 1996; Morello et al. 2001; Yoshida et al. 2003). 
While MET is primarily expressed in epithelial and lymphatic cells, its ligand 
hepatocyte growth factor (HGF) is only expressed and secreted from cells of 
mesenchymal origin through stimulation of IL-1α secreted from keratinocytes 
(Zarnegar 1995). The MET/HGF signaling pathway plays an important role in 
embryonic development and tumor growth by inducing mitogenesis, motogenesis, 
morphogenesis and angiogenesis (Bladt et al. 1995; Birchmeier and Gherardi 1998). 
Furthermore it is involved in wound healing, invasive growth and metastasis 
(Danilkovitch-Miagkova and Zbar 2002; Chmielowiec et al. 2007). The AKT signaling 
pathway plays a central role in the anti-apoptotic response induced by MET, for 
example in the HGF-mediated inhibition of UVB-induced apoptosis of human 
keratinocytes (Mildner et al. 2002; Tulasne and Foveau 2008). It was also 
demonstrated that supernatants of UVB-irradiated keratinocytes strongly induce HGF 
production in fibroblasts, and that this effect was primarily mediated by IL-1α (Mildner 
et al. 2007). The oncogenic potential of this pathway becomes especially apparent in 
transgenic mice expressing HGF in a variety of tissues. These mice develop 
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metastatic tumors (Takayama et al. 1997). Cells co-expressing MET and HGF 
become tumorigenic, when implanted into nude mice (Rong et al. 1994). The 
decrease of miRNA-206 in HPV8-CER mice confirmed by qRT-PCR and ISH starting 
two days after UV-irradiation should therefore lead to an enhanced expression of 
MET. This upregulation of MET was verified by IHC. Because MET is involved in 
many processes, which can lead to tumorigenesis, if dysregulated, the upregulation 
of this factor in HPV8-CER mice after UV-irradiation is a further effect of HPV8 which 
promotes papilloma development (Figure 22). 
The targets of the downregulated miRNA-374-5p and miRNA-689 are currently not 
known. Table 3 shows a list of predicted targets generated with a software tool from 
http://www.microrna.org. It is noteworthy that both miRNAs are possibly targeting the 
TGF-β pathway (miRNA-374 - LTBP1; miRNA-689 - TGFBR2). The reduced 
expression of these miRNAs would result in an activation of this pathway, thereby 
possibly promoting papillomatosis. 
The expression alterations measured for miRNA-17-5p, -20b, -21 and -106a in 
irradiated HPV8-E6 mice are supporting the results obtained from irradiated HPV8-
CER mice, which showed similar deregulations of miRNA expression. Furthermore, 
this shows that the similar phenotype of HPV8-CER and -E6 mice is reflected by 
comparable miRNA deregulations. 
The observation that human keratinocytes transduced with HPV8 showed the same 
tendency in expression alterations of miRNA17-5p, -20b, -21, -106a, -206 and -374-
5p as UV-irradiated HPV8-CER mice, is approving the assumption that HPV8 also 
deregulates these miRNAs in humans. 
It is remarkable that the deregulated miRNA targets KGF, MET, PDCD4, PTEN and 
Rb are all involved in the AKT signaling pathway which influences a broad spectrum 
of essential cell functions known to cause carcinogenesis, if dysregulated (Figure 
22). This indicates that the AKT pathway is important for the HPV8-mediated 
papillomatosis. However, it is most likely that the MAPK pathway is also influenced 
by most of these factors. In summary it was shown that the increase of HPV8 
oncogene expression was paralleled by a deregulation of tumorigenic and oncogenic 
miRNAs and their respective targets in UV-irradiated HPV8-CER mice. If cellular 
processes interacting with the induction of tumor growth are initiated by the 
enhanced expression of the HPV8 oncogene or by UVA/B-irradiation/wounding 
remains to be elucidated. 
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Figure 22: Model how HPV8 can interfere with cellular gene expression via miRNA deregulation 
Green objects represent confirmed upregulation, red objects represents confirmed downregulation. (1) 
After UV-irradiation keratinocytes release IL-1α which in turn leads to secretion of KGF, HGF and 
TGF-β from the fibroblasts. TGF-β activates the K14-promoter in keratinocytes. (2) The enhanced 
expression of KGF and MET due to miRNA-206 downregulation lead to the increased phosphorylation 
of PIP2 to PIP3 by PI3K, but also to the activation of the MAPK pathway. (3) The phosphorylation of 
PIP2 can be inhibited by PTEN, however PTEN is downregulated by miRNA-17-5p and miRNA-21. (4) 
PIP3 recruits AKT to the cell membrane where it is activated by phosphorylation. (5) The PDCD4-
mediated block of this translation initiation via inhibition of the helicase activity of EIF4A, is prevented 
by the reduced expression of PDCD4 mediated through miRNA-21. (6) The progression of the cell 
cycle is induced by phosphorylation of Rb which releases the transcription factor E2F. The release of 
E2F from Rb is furthermore facilitated by the downregulation of Rb by overexpressed miRNA-106a.  
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Table 3: Predicted targets for miRNA-374-5p and miRNA-689. 
The list is prepared with a prediction tool from http://www.microrna.org 
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AA   amino acid 
AEC   3-amino-9-ethylcarbazole 
AK   actinic keratosis 
AP-1   activator protein 1 
ATP   adenosine triphosphate 
B2M   beta-2-microglobulin 
bp   base pair 
BSA    bovine serum albumin 
CDK   cyclin-dependent kinase 
CRPV   cottontail rabbit papillomavirus 
DAB   3,3'-Diaminobenzidine 
DAPI   4′,6-diamidino-2-phenylindol 
Dig   digoxigenin 
DMBA   dimethylbenzanthracene 
DMEM  Dulbecco’s modified Eagle's medium 
DMSO   dimethyl sulfoxide 
DNA    deoxyribonucleic acid 
dNTP    deoxynucleoside triphosphate 
dsRBD  double-stranded RNA-binding domain 
dsRNAs  double stranded RNAs 
E6-AP  E6-associated protein 
E. coli   Escherichia coli 
EDTA   ethylenediaminetetraacetate 
EIF4A   eukaryotic translation initiation factor 4A 
EV   epidermodysplasia verruciformis 
FCS   fetal calf serum 
FVB/N   Friend leukaemia virus B strain 
g   gravitational acceleration 
CER   complete early region (of the HPV8 genome) 
h    human 
hDlg   human discs large (drosophila) homolog 
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HE-staining  hematoxylin and eosin staining 
HGF   hepatocyte growth factor 
HPLC   high pressure liquid chromatography 
HPRT1  hypoxanthine phosphoribosyltransferase 1 
HPV   human papillomvirus 
HPV8-CER  mouse strain transgenic for the complete early region of HPV8 
hScrib   human scribble (drosophila) homolog 
Hz   hertz 
IHC   immunohistochemistry 
IL1-α   interleukin 1-α 
ISH   in situ hybridization 
K14   keratin 14 
kb   kilobase  
kDa    kilodalton 
KGF   keratinocyte growth factor 
LB-medium  Luria Bertani medium 
LTBP1  latent transforming growth factor beta binding protein 1  
LTR   long terminal repeat 
µM   micromolar 
m   murine 
MAGUK  membrane associated guanylate kinase 
MAPK   mitogen-activated protein kinase 
MET   mesenchymal-epithelial transition factor 
min   minute 
miRNA  microRNA 
mM   millimolar 
mRNA  messenger ribonucleic acid 
mTOR  mammalian target of rapamycin 
MUPP1   multiple-PDZ domain protein 
MW   molecular weight 
NCR   non-coding region 
nM   nanomolar 
NMSC  non-melanoma skin cancer 
nt   nucleotide 
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OD   optical density 
ORF   open reading frame 
ori   origin of replication 
P-bodies  processing bodies 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PDCD4  programmed cell death 4 
PDZ   PSD-95, Dlg, Zo-1 
PEG   polyethylene glycol 
PI3K   phosphoinositide-3-kinase 
PIP2   phosphatidylinositol 4,5-bisphosphate 
PIP3    phosphatidylinositol-3,4,5-trisphosphate  
POD    peroxidase 
pre-miRNA  precursor miRNA 
pri-miRNA  primary miRNA 
PTEN   phosphatase and tensin homolog 
PV   papillomvirus 
qPCR   quantitative polymerase chain reaction 
qRT-PCR  quantitative real-time polymerase chain reaction 
Rb   retinoblastoma protein 1 
RISC   RNA-induced silencing complex 
RNA   ribonucleic acid 
RNAi   RNA interference 
rpm   rounds per minute 
RT   room temperature 
SCC   squamous cell carcinoma 
SDS   sodium dodecyl sulfate 
siRNA   small interfering RNA 
Sp1   Specific protein 1 
TBP   TATA binding protein 
TGF-β  transforming growth factor-β 
TGFBR2  transforming growth factor β receptor 2 
TPA   12-O-tetradecanoylphorbol-13-acetate 
TRBP   trans-activation-responsive RNA-binding protein 
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Tris   tris(hydroxymethyl)aminomethane 
TSB-medium transformation and storage medium 
u   atomic mass unit 
UV   ultraviolet 
VLP   virus like particles 
WHO   World Health Organization 
wt   wild type 
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8 Abstract 
 
An active role of cutaneous human papillomaviruses (HPV) in the pathogenesis of 
non-melanoma skin cancer (NMSC) in the general population is currently discussed. 
At least in immunosuppressed and epidermodysplasia verruciformis patients, an 
association between cutaneous HPV and NMSC is accepted. An oncogenic potential 
of the cutaneous HPV type 8 could be demonstrated in a transgenic mouse model, 
expressing all early genes of HPV8 (HPV8-CER), which shows spontaneous 
papilloma development, predominantly on scratched skin areas. A single UVA/B-
dose induces papillomatosis within three weeks in these mice, while the skin of 
FVB/N wild type mice heals completely within this time. In order to clarify the role of 
skin wounding and its influence on HPV gene expression in the early stages of tumor 
development in this mouse model, the kinetics and levels of transgene expression 
were analyzed in response to exogenous skin irritations induced by UVA/B-irradiation 
or mechanical wounding. Already on day one after irradiation enhanced HPV8 mRNA 
and protein levels were determined in the skin of HPV8-CER mice, which were 
preserved during the whole observation period of 30 days. Analogously in HPV8-E2 
and -E6 mice papilloma development was also paralleled by enhanced transgene 
expression. Mechanically irritated skin also showed an enhanced HPV8 oncogene 
expression in HPV8-CER mice two days after irritation, which could be knocked-
down by tattooing HPV8-E6-specific small interfering RNA leading to a delay and a 
lower incidence of papilloma development. This substantiates the hypothesis that the 
early HPV8 gene expression after wounding is crucial for papillomatosis in mice. The 
expression kinetics of selected cellular microRNAs (miRNAs) and their targets were 
determined after induction of papillomatosis to check for a correlation with HPV8 
oncogene expression. Several miRNAs (miRNA-17-5p, -21, -106a, -155, -206) and 
their targets (PTEN, PDCD4, Rb, KGF, MET) showed expression alterations often 
found to be associated with carcinogenesis. The alterations occurred in parallel to the 
increase of HPV8 oncogene expression, which raises the assumption that HPV8 can 
directly or indirectly induce these alterations. 
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9 Zusammenfassung 
 
Eine aktive Rolle von kutanen humanen Papillomviren (HPV)  bei der Pathogenese 
von nicht-melanozytärem Hautkrebs (NMHK) wird zurzeit diskutiert. Eine Verbindung 
zwischen kutanen HPV und NMHK ist zumindest für immunsupprimierte und 
Epidermodysplasia verruciformis Patienten akzeptiert. Für den kutanen HPV Typ 8 
konnte ein onkogenes Potential in einem transgenen Mausmodell gezeigt werden, 
welches alle frühen Gene von HPV8 exprimiert (HPV8-GFR). Diese Tiere entwickeln 
spontan Papillome, überwiegend auf zerkratzten Hautarealen. Eine einzige 
Bestrahlung mit UVA/B induziert in diesen Mäusen eine Papillomatose innerhalb von 
drei Wochen, während die Haut von FVB/N Wildtyp Mäusen in dieser Zeit vollständig 
verheilt. Um die Rolle der Hautverletzung und ihren Einfluss auf die HPV 
Genexpression in den frühen Stadien der Tumorentwicklung in diesem Mausmodell 
zu klären, wurden die Kinetik und Höhe der Transgenexpression analysiert als 
Antwort auf exogene Hautreizungen, verursacht durch UVA/B-Bestrahlung oder 
mechanische Verwundung. Bereits einen Tag nach Bestrahlung wurden erhöhte 
HPV8 mRNA und Protein Spiegel in der Haut von HPV8-GFR Mäusen ermittelt, die 
während der gesamten Beobachtungsdauer von 30 Tagen erhalten blieben. Analog 
dazu war die Papillomentwicklung in HPV8-E2 und HPV8-E6 Mäusen ebenfalls 
begleitet von einer erhöhten Transgenexpression. Mechanisch gereizte Haut zeigte 
ebenfalls eine erhöhte HPV8 Onkogenexpression in HPV8-GFR Mäusen zwei Tage 
nach der Reizung. Diese Expression konnte durch tätowieren einer HPV8-E6-
spezifischen small interfering RNA unterdrückt werden, was die Papillomentwicklung 
verzögerte und reduzierte. Dies untermauert die Hypothese, dass die frühe HPV8 
Genexpression nach der Verwundung entscheidend für die Papillomatose in Mäusen 
ist. Die Expressionskinetiken von ausgewählten microRNAs (miRNAs) und deren 
Zielgenen wurden nach Induktion der Papillomatose ermittelt, um zu prüfen, ob sie 
mit der HPV8 Onkogenexpression korrelieren. Mehrere miRNAs (miRNA-17-5p, -21, 
-106a, -155, -206) und deren Zielgene (PTEN, PDCD4, Rb, KGF, MET) zeigten 
Expressionsveränderungen die bekanntermaßen mit Karzinogenese assoziiert sind. 
Die Veränderungen wurden von einem Anstieg der HPV8 Onkogenexpression 
begleitet, was die Vermutung aufkommen lässt, dass HPV8 diese Veränderungen 
direkt oder indirekt induzieren kann. 
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